Medtronic DTPA2Q1 Implant Manual

Cobalt™ XT HF Quad CRT-D MRI SureScan™ DTPA2Q1

MR Conditional implantable cardioverter defibrillator with cardiac resynchronization therapy, SureScan™ technology, and Bluetooth® wireless telemetry (DDE-DDDR)

Device Manual

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

Medtronic, Medtronic with rising man logo, and Medtronic logo are trademarks of Medtronic. Third-party trademarks (“TM*”) belong to their respective owners. The following list includes trademarks or registered trademarks of a Medtronic entity in the United States and/or in other countries.

Active Can™, AdaptivCRT™, BlueSync™, Capture Management™, Cardiac Compass™, CardioSync™, CareAlert™, CareLink™, ChargeSaver™, Cobalt™, EffectivCRT™, Evera MRI™, Evera™, Intrinsic ATP™, Jewel™, Medtronic CareAlert™, Medtronic CareLink™, MVP™, OptiVol™, PhysioCurve™, PR Logic™, Protecta™, Quick Look™, Reactive ATP™, SmartShock™, SureScan™, T-Shock™, TriageHF™, VectorExpress™

1 System overview 4

1.1 Introduction 4

1.2 System description 4

1.3 Indications and usage 5

1.4 Contraindications 6

1.5 MRI conditions for use 6

1.6 Pre-implant consideration 7

1.7 Feature summary 7

1.8 Data security 12

2 Warnings, precautions, and potential adverse events 12

2.1 General warnings and precautions 12

2.2 Explant and disposal 13

2.3 Handling and storage instructions 13

2.4 Lead evaluation and lead connection 14

2.5 Device operation 14

2.6 Potential adverse events 16

3 Clinical data 17

3.1 Adverse events and clinical trial data 17

4 Implant procedure 18

4.1 Preparing for an implant 18

4.2 Selecting and implanting the leads 20

4.3 Testing the lead system 21

4.4 Connecting the leads to the device 22

4.5 Performing ventricular defibrillation threshold tests 25

4.6 Positioning and securing the device 25

4.7 Completing the implant procedure 26

4.8 Replacing a device 27

5 Product specifications 28

5.1 Physical characteristics 28

5.2 Replacement indicators 30

5.3 Projected service life 30

5.4 Energy levels and typical charge times 32

5.5 Magnet application 32

5.6 Wireless specifications 32

6 Device parameters 33

6.1 Emergency settings 33

6.2 Tachyarrhythmia detection parameters 34

6.3 Atrial tachyarrhythmia therapy parameters 35

6.4 Ventricular tachyarrhythmia therapy parameters 38

6.5 Pacing parameters 40

6.6 Medtronic CareAlert parameters 47

6.7 Data collection parameters 49

6.8 System test parameters 51

6.9 EP Study parameters 52

1 System overview

1.1 Introduction

This manual describes the Medtronic Model DTPA2Q1 Cobalt XT HF Quad CRT-D MRI SureScan dual chamber, implantable cardioverter defibrillator with cardiac resynchronization therapy (CRT-D). It contains model-specific feature information, indications and contraindications, warnings and precautions, instructions for implanting the device, quick reference specifications, and parameter tables.

The following manuals and documents also contain information about the device:

MRI technical manual – This manual provides MRI-specific procedures and warnings and precautions.

Reference manual – This manual includes information about device features. The reference manual applies to

multiple models of CRT-D devices.

Implantable device app help – The help explains how to use the implantable device app to program the device settings and view the stored device data.

Explanation of symbols – This document defines the symbols that may appear on the device package. Refer to the package label to see which symbols apply specifically to this device.

Medical Procedure and EMI Warnings, Precautions, and Guidance Manual for Health Care Professionals – This manual provides warnings, precautions, and guidance for health care professionals who

perform medical therapies and diagnostic procedures on cardiac device patients. This manual also includes information about hazards from sources of electromagnetic interference (EMI) in the patient’s home, recreational environments, and occupational environments.

Radio regulatory compliance information – This document provides compliance information related to the radio components of the device.

1.2 System description

The Model DTPA2Q1 dual chamber, implantable cardioverter defibrillator with cardiac resynchronization therapy (CRT-D) is a multiprogrammable cardiac device that monitors and regulates the patient’s heart rate by providing single or dual chamber, rate-responsive bradycardia pacing; sequential biventricular pacing; ventricular tachyarrhythmia therapies; and atrial tachyarrhythmia therapies. This device features Bluetooth wireless technology.

The device can detect ventricular tachycardia and ventricular fibrillation (VT/VF) automatically and provide treatment with defibrillation, cardioversion, and antitachycardia pacing therapies. The device can also detect atrial tachycardia and atrial fibrillation (AT/AF) automatically and provide treatment with cardioversion and antitachycardia pacing therapies. Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device responds to bradyarrhythmias by providing bradycardia pacing therapies.

The MRI SureScan feature permits a mode of operation that allows a patient with a SureScan system to be safely scanned by an MRI machine while the device continues to provide appropriate bradycardia pacing. When programmed to On, MRI SureScan operation disables arrhythmia detection and all user-defined diagnostics. Before performing an MRI scan, refer to the MRI technical manual.

The device also provides diagnostic and monitoring information that assists with system evaluation and patient care.

The Bluetooth® word mark is a registered trademark of Bluetooth SIG, Inc. and any use of this mark by Medtronic is under license.

1.2.1 Usage environments

The device is intended to be used in the following environments and conditions:

• The device will be implanted in a properly equipped, staffed, and sterile surgical environment. Implant will take place under standard surgical protocols and in the patient population for which the device is indicated.

• Post-surgical patient and device follow-up care will take place in a properly equipped and staffed cardiology clinic or office.

• MRI procedures for patients with this device will take place in a properly equipped and staffed MR facility, and in consideration of the conditions and requirements described in Section 1.5.

• After having an implant, patients may resume their lives at home, at work, and in other environments with consideration of the advice and restrictions documented in the Medical Procedure and EMI Warnings, Precautions, and Guidance Manual for Health Care Professionals and in the patient literature.

1.2.2 System components and accessories

Contents of sterile package – The package contains 1 implantable cardioverter defibrillator, 1 Medtronic DF-1

pin plug, and 1 torque wrench.

Connectors – The device has the IS4 inline connector, which facilitates the connection of an IS4–LLLL quadripolar left ventricular (LV) lead during the implant. IS4–LLLL refers to the international standard ISO 27186, where the lead connector contacts are defined as low voltage (L).

Leads – The lead system used with this device must provide pacing to the left ventricle (LV); sensing, pacing, cardioversion, and defibrillation therapies to the right ventricle (RV); and sensing and pacing to the atrium (A). Do not use any lead with this device without first verifying lead and connector compatibility.

For information about selecting and implanting leads for this device, refer to Section 4.2, Selecting and implanting the leads, page 20.

Implantable device system – The Model DTPA2Q1 device, the pacing leads, and the defibrillation leads constitute the implantable portion of the device system.

Device manager – Healthcare professionals and Medtronic representatives use the device manager in a clinical or hospital environment to perform implant and follow-up procedures. The device manager consists of a base, a patient connector, and a device manager app installed on a tablet. The device manager app is the primary interface of the device manager and provides access to the implantable device app and the analyzer. For more information, refer to the device manager instructions for use, including the help.

Programmers from other manufacturers are not compatible with Medtronic devices, but they do not damage Medtronic devices.

Home communicator – Patients use the home communicator to gather information automatically from their implanted device and communicate the information to their physicians through the Medtronic CareLink Network. For information on using the home communicator, refer to the home communicator instructions for use.

Patient app – Patients use the patient app to transmit information from their implanted device to their physicians through the Medtronic CareLink Network. For information on using the patient app, refer to the patient app instructions for use.

1.3 Indications and usage

The Model DTPA2Q1 device is indicated for use in patients who are at significant risk of developing atrial and/or life-threatening ventricular arrhythmias and who have heart failure with ventricular arrhythmias. Heart failure patients must have experienced one or more of the following conditions:

• NYHA Functional Class III or IV patients who remain symptomatic despite stable, optimal medical therapy and have LVEF ≤35% and a prolonged QRS duration

• NYHA Functional Class II patients who have left bundle branch block (LBBB) with a QRS duration ≥130 ms and a left ventricular ejection fraction ≤30%

• NYHA Functional Class I, II, or III who are on stable, optimal medical therapy (if indicated) and have LVEF ≤50%, atrioventricular block (AV block), and are expected to require a high percentage of ventricular pacing that cannot be managed with algorithms to minimize right ventricular pacing

Note: For patient-specific recommendations such as primary and secondary preventions, refer to current clinical guidelines.

1.4 Contraindications

The Model DTPA2Q1 device is contraindicated for use in the following situations:

• If implanted with a unipolar pacemaker

• If incessant VT or VF exists

• If the primary disorder is chronic atrial tachyarrhythmia with no concomitant VT or VF

• If tachyarrhythmias with transient or reversible causes exist, including the following known issues: – acute myocardial infarction – drug intoxication – drowning – electric shock – electrolyte imbalance – hypoxia – sepsis

1.5 MRI conditions for use

A complete SureScan defibrillation system is required for use in the MR environment. Any other combination may result in a hazard to the patient during an MRI scan.

A complete SureScan defibrillation system includes the following components:

• The Model DTPA2Q1 device

• A SureScan right atrial pacing lead or a Model 6725 pin plug for the right atrial port

• A SureScan left ventricular pacing lead

• A SureScan defibrillation lead. When a single coil SureScan defibrillation lead is used, a Medtronic DF-1 pin plug must be secured in the SVC port to make a complete SureScan defibrillation system.

A complete SureScan system only includes components that have been certified by Medtronic as being MR Conditional. To verify that components are part of a SureScan system, visit http://www.mrisurescan.com.

Before performing an MRI scan, refer to the MRI technical manual for MRI-specific warnings and precautions.

Warning: Do not scan a patient without first programming the MRI SureScan mode to On. Scanning the patient without programming the MRI SureScan mode to On may result in patient harm or damage to the SureScan system.

Note: The MRI SureScan mode cannot be programmed to On if the device is recommended for replacement.

Note: The LV chamber can be paced during SureScan operation at the programmed pacing output and pulse

width if the LV lead polarity does not include the RVcoil.

Cardiology requirements

Patients and their implanted systems must be screened to meet the following requirements:

• The patient has no implanted lead extenders, lead adaptors, or abandoned leads.

• The patient has no broken leads or leads with intermittent electrical contact, as confirmed by lead impedance history.

• The SureScan system is implanted in the left or the right pectoral region.

• The SureScan device is operating within the projected service life.

• For patients whose device will be programmed to an asynchronous pacing mode or biventricular pacing mode when the MRI SureScan mode is programmed to On, no diaphragmatic stimulation is present when the paced leads have a pacing output of 5.0 V and a pulse width of 1.0 ms.

Caution: For pacemaker-dependent patients, it is not recommended to perform an MRI scan if the right ventricular (RV) lead pacing capture threshold is greater than 2.0 V at 0.4 ms. A higher pacing capture threshold may indicate an issue with the implanted lead.

Patient monitoring and rescue requirements

• Continuous patient monitoring is required while the MRI SureScan mode is programmed to On.

• If patient rescue is required, an external defibrillator must be immediately available.

Training requirements

• A health professional who has completed cardiology SureScan training must be present during the programming of the MRI SureScan feature.

• A health professional who has completed radiology SureScan training must be present during the MRI scan.

Note: For radiology requirements for an MRI scan, refer to the MRI technical manual.

1.6 Pre-implant consideration

Patient evaluation for the implant of the Model DTPA2Q1 system should include the following consideration about a concomitant implant with a neurostimulator:

Concomitant neurostimulator and cardiac device implants – Some patients have medical conditions that require the implant of both a neurostimulator and a cardiac device (for example, a pacemaker, a defibrillator, or a monitor). In this case, physicians (for example, a neurologist, a neurosurgeon, a cardiologist, and a cardiac surgeon) involved with either device should contact Medtronic Technical Services or their Medtronic representative before implanting the patient with the second device. Based on the particular devices that the physicians have prescribed, Medtronic can provide the necessary precautions and warnings related to the implant procedure. For information about how to contact Medtronic, see the telephone numbers and addresses provided on the back cover of this manual.

1.7 Feature summary

The following features are available in this device. For a list of the features that are enabled at shipping, see the “Shipped” column of the tables in Chapter 6, Device parameters, page 33.

For more information about these features, see the reference manual and the implantable device app help.

1.7.1 Tachyarrhythmia detection features

Note: When the MRI SureScan mode is programmed to On, tachyarrhythmia detection and therapies are

suspended. Before performing an MRI scan, refer to the MRI technical manual for MRI-specific warnings and precautions.

AT/AF detection – This feature analyzes the atrial rate and its effect on the ventricular rhythm to determine whether the patient is currently experiencing an atrial tachyarrhythmia. Evidence of an atrial tachyarrhythmia is based on the number and timing of atrial events during ventricular intervals. Depending on programming, the device delivers a programmed sequence of atrial therapies or continues monitoring without delivering therapy.

High Rate Timeout – This feature allows the device to deliver therapy for any ventricular tachyarrhythmia that continues beyond the programmed length of time.

Onset – This feature helps prevent the detection of sinus tachycardia as VT by evaluating the acceleration of the ventricular rate.

Reactive ATP algorithm – This feature allows the device to deliver atrial ATP therapies that had been unsuccessful earlier in an AT/AF episode. The device repeats the delivery of atrial ATP therapies after the programmed time interval or when the atrial rhythm changes.

SmartShock 2.0+ technology – A collection of VT/VF detection and therapy features designed to reduce the incidence of inappropriate or unnecessary shocks. These features include Confirmation+, Intrinsic ATP algorithm (see Section 1.7.2, Tachyarrhythmia therapy features, page 8), PR Logic + Wavelet, RV Lead Integrity Alert, RV Lead Noise Discrimination, SVT Discriminators in VF Zone, and TWave Discrimination.

• Confirmation+ – The Confirmation+ feature identifies if a tachycardia has been terminated with ATP or has spontaneously ended during the charge. The Confirmation+ feature identifies and cancels a pending defibrillation shock. The Confirmation+ feature avoids inappropriate shocks for single PVCs or single fast events at the end of the charge.

• PR Logic + Wavelet – The PR Logic feature uses pattern and rate analysis to discriminate between supraventricular tachycardias (SVTs) and true ventricular tachyarrhythmias. The Wavelet feature prevents detection of rapidly conducted SVTs as ventricular tachyarrhythmias by comparing the shape of each QRS complex during a fast ventricular rate to a template.

• RV Lead Integrity Alert – The RV Lead Integrity Alert feature sounds an alert tone when a potential lead problem is suspected. When the alert criteria are met, device settings are automatically adjusted to prevent delivery of inappropriate and unnecessary therapy.

• RV Lead Noise Discrimination and Alert – The RV Lead Noise Discrimination and Alert feature identifies lead noise due to a suspected lead problem. This feature withholds VT/VF detection to prevent delivery of inappropriate therapy. An alert tone can be programmed to notify the patient.

• SVT Discriminators in VF Zone – The SVT Discriminators in VF Zone feature limits nominal changes to 260 ms with high rate timeout.

• TWave Discrimination – The TWave Discrimination feature withholds VT/VF detection when a fast ventricular rate is detected due to sensed T-waves, avoiding delivery of inappropriate therapy.

Stability – This feature helps to prevent the detection of atrial fibrillation as ventricular tachyarrhythmia by evaluating the stability of the ventricular rate. If the device determines that the ventricular rate is not stable, it withholds VT detection.

VT/VF detection – This feature uses programmable detection zones to classify ventricular events. If the number of tachyarrhythmia events in a zone exceeds a programmed threshold, the device detects a ventricular tachyarrhythmia episode. Depending on programming, the device delivers a scheduled therapy, re-evaluates the patient’s heart rhythm, and terminates or redetects the episode.

1.7.2 Tachyarrhythmia therapy features

Note: When the MRI SureScan mode is programmed to On, tachyarrhythmia detection and therapies are

suspended. Before performing an MRI scan, refer to the MRI technical manual for MRI-specific warnings and precautions.

Atrial therapy scheduling – This feature enables the clinician to program the delivery of automatic atrial therapies. Each time that an AT/AF therapy is needed, the device schedules one of the available therapies based on clinician programming.

Atrial cardioversion – This therapy delivers a high-voltage shock to treat an AT/AF episode or a Fast AT/AF episode. Atrial cardioversion delivery is synchronized to a sensed ventricular event and cannot exceed a programmable daily limit within programmable times.

Programmable Active Can and SVC electrodes – The device provides the capability to disable either the Active Can or the SVC electrode as part of the high-voltage therapy delivery pathway.

Progressive Episodes Therapies – This feature causes the device to skip therapies or modify high-voltage energy levels to ensure that each therapy delivered during an episode is at least as aggressive as the previous therapy.

Ventricular fibrillation (VF) therapies – The device delivers defibrillation shocks to treat VF episodes. VF must be detected and then confirmed before the first shock is delivered. If the first shock does not terminate the VF episode, subsequent shocks are delivered. The device can also be programmed to deliver ventricular antitachycardia pacing (ATP) therapy during charging, or before and during charging for the first defibrillation shock. ATP therapy attempts to terminate a ventricular tachyarrhythmia that might not require a defibrillation shock.

Ventricular antitachycardia pacing (ATP) – These therapies respond to a VT episode or an FVT episode with rapid sequences of pacing pulses to terminate detected ventricular tachyarrhythmias. Therapy options include Burst, Ramp, Ramp+, and iATP. Burst, Ramp, and Ramp+ all have a programmable number of sequences, while iATP automatically sets ATP sequences tailored for the patient.

Intrinsic ATP algorithm – Intrinsic ATP (iATP) is an automated ATP therapy for reentrant ventricular tachycardia (VT). iATP uses heart rate history to design the first ATP sequence and analyzes the result of each ATP sequence in real-time to design the next ATP sequence, if necessary. iATP delivers ATP until it terminates VT or reaches its programmed number of ATP sequences. If iATP does not terminate VT, the device progresses to the next programmed therapy.

Ventricular cardioversion – This therapy delivers a high-voltage shock to treat a VT episode or an FVT episode. Therapy is synchronized to a sensed ventricular event.

1.7.3 Diagnostic data features

Note: When the MRI SureScan mode is programmed to On, tachyarrhythmia detection and therapies are

suspended. Before performing an MRI scan, refer to the MRI technical manual for MRI-specific warnings and precautions.

Quick Look – This feature presents overview data about device operation and patient rhythms collected since the last patient session. It includes links to more detailed status and diagnostic information stored in the device, such as arrhythmia episodes, EffectivCRT episodes, capture thresholds, and therapies provided.

Medtronic CareAlert Monitoring – If the device identifies any programmed or automatic CareAlert conditions, this feature sends a wireless alert signal to the home communicator or the patient app. The home communicator or the patient app then transmits the CareAlert event data to the Medtronic CareLink Network. If configured to do so, the Medtronic CareLink Network then sends an alert notification to the clinic.

TriageHF Technology Compatible – When the TriageHF feature is enabled on your CareLink network account, the integrated heart failure risk status feature will be available with any CareLink transmission once 65 days or more of long-term clinical trend data is collected by the device. Contact your Medtronic representative about how to enable the TriageHF feature on your CareLink network account. For more information about this feature, see the TriageHF heart failure risk status technical manual on the Medtronic Manual Library website (www.medtronic.com/manuals).

OptiVol 2.0 Fluid Status Monitoring – This feature identifies a potential increase in thoracic fluid, which may indicate lung congestion, by monitoring changes in thoracic impedance. If the change exceeds the programmed threshold, an alert tone sounds to notify the patient to seek medical attention.

Cardiac Compass Trends – This feature provides a Cardiac Compass Report that shows an overview of the patient’s condition with graphs that display the long-term trends in heart rhythm over the last 14 months. The report also includes the OptiVol 2.0 fluid trend data.

Heart Failure Management Report – This report provides an overview of the patient’s condition over the short term and the long term with a focus on heart failure management. The report includes graphs that show the OptiVol

2.0 fluid trends and the trends related to heart failure over the last 14 months.

Arrhythmia episode data – The system compiles an arrhythmia episode log that the clinician can use to view summary and detailed diagnostic data quickly, including stored EGM, for the selected arrhythmia episode. Also available are episode and therapy counters showing the number of times that arrhythmias and therapies have occurred.

Flashback Memory – This diagnostic feature records the intervals that immediately preceded tachyarrhythmia episodes or that preceded the last interrogation of the device and plots the interval data over time.

Ventricular sensing episodes data – This feature compiles diagnostic information to help the clinician identify the cause of ventricular sensing episodes and reprogram the device to avoid these episodes. Data collected includes the date and time, the duration, the intervals and markers, the maximum atrial and ventricular rates, and an indication of whether the episode was part of a tachyarrhythmia.

Rate Drop Response episodes data – This feature displays beat-to-beat data that is useful in analyzing Rate Drop Response episodes and the events leading up to these episodes. The feature records data about episodes that meet the programmed rate drop detection criteria.

Rate Histograms – This diagnostic feature reports the atrial and ventricular event data stored by the device, including histograms for atrial rate, ventricular rate, and ventricular rate during AT/AF. Rate histograms also report data about the patient’s conduction status, ventricular pacing and sensing, and CRT pacing.

EffectivCRT episodes data – This feature compiles diagnostic information to help the clinician identify the cause of ineffective CRT pacing and to reprogram the device to avoid it. Data collected includes the date and time, the average atrial and ventricular beats per minute, the event markers, an indication of whether AT/AF was present, and an indication of which ventricular paces were effective.

1.7.4 Pacing features

CRT ventricular pacing options – The ventricular pacing configuration in the CRT device provides the

programming option for biventricular pacing, RV-only pacing, or LV-only pacing. The biventricular pacing sequence and V-V pace delay are programmable as an additional means to improve hemodynamics.

AdaptivCRT algorithm – This feature adjusts CRT parameter values automatically while the patient is ambulatory. If the AdaptivCRT feature is programmed to Adaptive Bi-V and LV, the feature can switch automatically between biventricular pacing and LV-only pacing.

MVP (Managed Ventricular Pacing) – The MVP feature promotes intrinsic conduction by reducing unnecessary right ventricular pacing. This feature operates when the programmed mode is either AAIR<=>DDDR or AAI<=>DDD.

EffectivCRT During AF algorithm – This feature dynamically adjusts the pacing rate in response to changes in the percentage of effective CRT pacing to promote CRT delivery in nontracking modes.

LV Pacing Polarity – This feature provides 16 pacing polarities the clinician can select from to identify a pacing polarity that provides capture at the desired site, maximizes device longevity, and avoids phrenic nerve stimulation. The LV pacing polarity selections include 12 bipolar vectors and 4 extended bipolar vectors. The feature also enables the clinician to change pacing location, if necessary, by programming pacing polarity.

Rate Response – This feature adjusts the cardiac pacing rate in response to changes in sensed patient activity.

Rate Profile Optimization – This feature monitors the patient’s daily and monthly sensor rate profiles and adjusts

the rate response curves over time to achieve a prescribed target rate profile. The goal is to ensure that the rate response remains appropriate for the full range of patient activities.

Capture Management – This feature monitors pacing thresholds with daily pacing threshold searches and, if programmed to do so, adjusts the pacing amplitudes toward a target amplitude.

Rate Adaptive AV – This dual-chamber pacing feature varies the paced AV intervals and the sensed AV intervals as the heart rate increases or decreases to maintain 1:1 tracking and AV synchrony.

Auto PVARP – This feature adjusts the post-ventricular atrial refractory period (PVARP) in response to changes in the patient’s heart rate or pacing rate. PVARP is longer at lower tracking rates to prevent pacemaker-mediated tachycardia and shorter at higher rates to maintain 1:1 tracking.

Rate Drop Response – This feature monitors the heart for a significant drop in rate and responds by pacing the heart at an elevated rate for a programmed duration.

Sleep – This feature causes the device to pace at a slower rate during a programmed sleep period.

Non-Competitive Atrial Pacing (NCAP) – This feature prohibits atrial pacing within a programmable interval

after a refractory atrial event.

PMT (pacemaker-mediated tachycardia) Intervention – This feature automatically detects and interrupts device-defined pacemaker-mediated tachycardias.

PVC Response – This feature extends PVARP following a premature ventricular contraction (PVC) to avoid tracking a retrograde P-wave and to prevent retrograde conduction from inhibiting an atrial pace.

Ventricular Safety Pacing (VSP) – This feature prevents inappropriate inhibition of ventricular pacing caused by crosstalk or ventricular oversensing.

Mode Switch – This feature switches the device pacing mode from a dual-chamber atrial tracking mode to a nontracking mode during an atrial tachyarrhythmia. This feature prevents rapid ventricular pacing that can result from tracking a high atrial rate and restores the programmed pacing mode when the atrial tachyarrhythmia ends.

Atrial Tracking Recovery – If atrial tracking is lost because of PVCs or because of an atrial rhythm that is too fast to be tracked to the ventricle, this feature temporarily shortens PVARP to restore atrial tracking and CRT delivery.

Multiple Point Pacing (MPP) – This feature enables the device to deliver 2 LV pulses per pace, with a programmable V-V delay, to 2 pacing vectors. Each LV pulse can be programmed with its own amplitude and pulse width.

Ventricular Sense Response (VSR) – This feature triggers ventricular pacing in response to ventricular sensing to ensure that CRT pacing is delivered as programmed.

Conducted AF Response – This feature dynamically adjusts and smooths the pacing rate to promote CRT delivery in the presence of sensed ventricular events in nontracking modes.

Atrial Rate Stabilization (ARS) – This feature adapts the atrial pacing rate in response to a PAC (premature atrial contraction) to avoid long sinus pauses following short atrial intervals.

Atrial Preference Pacing (APP) – This feature maintains a consistent activation sequence by providing continuous pacing that is closely matched to the intrinsic rate.

Post Mode Switch Overdrive Pacing (PMOP) – This feature works with the Mode Switch feature to deliver overdrive atrial pacing during the vulnerable phase following the termination of an AT/AF episode.

Post VT/VF Shock Pacing – This feature provides temporary overdrive pacing for a programmed duration after a ventricular high-voltage therapy.

Ventricular Rate Stabilization (VRS) – This feature adjusts the pacing rate dynamically to eliminate the long pause that typically follows a premature ventricular contraction (PVC).

1.7.5 Testing features

Underlying Rhythm Test – This feature temporarily inhibits the pacing output of the device to enable the clinician

to evaluate the patient’s intrinsic heart rhythm. During the test, the device is temporarily programmed to a nonpacing mode.

VectorExpress LV Automated Test – This feature allows automated testing of clinician-selected pacing polarities to determine the patient’s LV capture thresholds and pacing impedances. The feature also reports longevity information for tested LV pacing polarities, the results of phrenic nerve stimulation threshold tests, and delay information (RV sense to LV sense or RV pace to LV sense) for each LV electrode.

Pacing Threshold Test – This feature allows the clinician to determine the patient’s pacing thresholds and, in the LV, the phrenic nerve stimulation thresholds. Test results show the last impedance measurement and, when more than one LV pacing polarity has been tested, an indication of the impact on device longevity for each LV pacing polarity tested.

CardioSync Optimization Test – This feature measures the patient’s intrinsic AV intervals and the waveform widths of the P-wave and the QRS complex. Based on the measurements, the test provides optimized values for the following CRT parameters: the V. Pacing configuration, the V-V Pace Delay, the Paced AV, and the Sensed AV.

Wavelet Test – This feature evaluates the accuracy of the current wavelet template and allows the clinician to collect a new template, if necessary.

Lead Impedance Test – This feature tests the integrity of the implanted lead system by measuring the impedance of the pacing and high-voltage electrodes. The test uses low-voltage, subthreshold pulses to make these measurements.

Sensing Test – This feature measures P-wave and R-wave amplitudes to help the clinician assess lead integrity and sensing performance. Mode, AV Delay, and Lower Rate can be programmed temporarily so that the device is not pacing the patient’s heart, increasing the likelihood that sensed events will occur.

Charge/Dump Test – This feature tests the charge time of the capacitors and dumps any charge remaining on the capacitors.

EP Studies – This set of protocols allows clinicians to induce arrhythmias during electrophysiology studies. The available induction protocols are T-Shock, 50 Hz Burst, Fixed Burst, and Programmed Electrical Stimulation. Manual therapies are also available.

1.7.6 Additional operations

MRI SureScan – This feature allows patients to be scanned safely by an MRI machine when used according to

the specified MRI conditions for use. Refer to the MRI technical manual for additional information.

1.8 Data security

Medtronic has designed safeguards to protect patient information and device data for the Model DTPA2Q1 device.

BlueSync technology – The device uses Bluetooth wireless technology to communicate with the device manager, the patient app, and the home communicator. All data accepted or sent through the Bluetooth communication from the device is encrypted by the device before it is sent over the Bluetooth channel. The device responds only to authorized commands.

Inductive telemetry communication system – The Medtronic inductive telemetry communication system is used with the device manager to interrogate and program the device. This system uses short-range communication that protects patient information and device data.

2 Warnings, precautions, and potential adverse events

2.1 General warnings and precautions

A complete SureScan defibrillation system is required for use in the MR environment. Any other combination may result in a hazard to the patient during an MRI scan.

A complete SureScan defibrillation system includes the following components:

• The Model DTPA2Q1 device

• A SureScan right atrial pacing lead or a Model 6725 pin plug for the right atrial port

• A SureScan left ventricular pacing lead

Before performing an MRI scan, refer to the MRI technical manual for MRI-specific warnings and precautions.

Note: The MRI SureScan mode cannot be programmed to On if the device is recommended for replacement.

Note: The LV chamber can be paced during SureScan operation at the programmed pacing output and pulse width if the LV lead polarity does not include the RVcoil.

Refer to the Medical Procedure and EMI Warnings, Precautions, and Guidance Manual for Health Care Professionals for information about hazards related to medical therapies and diagnostic procedures on patients with cardiac devices. This manual also includes information about sources of EMI in the patient’s environment.

Medical procedure warnings and precautions that pertain to the Medtronic implanted system are provided in the manual that is packaged with the device or on the Medtronic Manual Library website (www.medtronic.com/manuals).

Avoiding shock during handling – Disable tachyarrhythmia detection during implant, explant, or postmortem procedures. The device can deliver a high-voltage shock if the defibrillation terminals are touched.

Electrical isolation during implant – Do not allow the patient to have contact with grounded electrical equipment that might produce electrical current leakage during implant. Electrical current leakage may induce tachyarrhythmias that may result in the patient’s death.

External defibrillation equipment – Keep external defibrillation equipment nearby for immediate use during acute lead system testing, the implant procedure, or whenever tachyarrhythmias are possible or intentionally induced during post-implant testing.

Note: An external defibrillator must be immediately available while the MRI SureScan mode is programmed to On.

Lead compatibility – Although Medtronic device connector modules conform to International Connector

Standards, this device has not been tested for use with non-Medtronic leads. The known potential adverse consequences of using such a combination may include undersensing of cardiac activity, failure to deliver necessary therapy, or an intermittent electrical connection.

Occurrence of stroke – Following an ischemic or a cerebrovascular accident, disable atrial cardioversion therapies until the patient has stabilized.

2.2 Explant and disposal

Consider the following information related to device explant and disposal:

• To prevent the device from delivering unwanted shocks, interrogate the device and disable tachyarrhythmia detection before explanting, cleaning, or shipping the device.

• Explant the implanted device postmortem. In some countries, explanting battery-operated implantable devices is mandatory because of environmental concerns; check the local regulations. In addition, the device may explode if subjected to incineration or cremation temperatures.

• The implantable device is intended for single use only. Do not resterilize and reimplant an explanted device.

• Contact Medtronic for Return Mailer Kits to return explanted devices for analysis and disposal. See the back cover for addresses. Note: Disposal of explanted devices or leads is subject to local, state, and federal regulations.

2.3 Handling and storage instructions

Carefully observe these guidelines when handling or storing the device.

2.3.1 Device handling

Checking and opening the package – Before opening the sterile package tray, visually check for any signs of

damage that might invalidate the sterility of the package contents.

Damaged package – The device packaging consists of an outer tray and an inner tray. Do not use the device or accessories if the outer packaging tray is wet, punctured, opened, or damaged. Return the device to Medtronic because the integrity of the sterile packaging or the device functionality may be compromised. This device is not intended to be resterilized.

Sterilization – Medtronic has sterilized the package contents with ethylene oxide before shipment. This product is for single use only and is not intended to be resterilized.

Dropped device – Do not implant the device if it is dropped on a hard surface from a height of 30 cm (12 in) or more after it is removed from its packaging.

Fluid immersion – Do not immerse the device in fluid or flush the connector ports at the time of implant. Doing so could adversely affect the performance of the device and lead system.

“Use by” date – Do not implant the device after the “Use by” date because the device longevity could be reduced.

2.3.2 Device storage

Avoid magnets – To avoid damaging the device, store the device in a clean area away from magnets, kits

containing magnets, and any sources of electromagnetic interference.

Temperature limits – Store and transport the package between –18°C and +55°C (0°F and 131°F). Electrical reset may occur at temperatures below –18°C (0°F). Device longevity may decrease and performance may be affected at temperatures above +55°C (131°F).

2.4 Lead evaluation and lead connection

Refer to the lead technical manuals for specific instructions and precautions about lead handling.

Torque wrench – Use only the torque wrench supplied with the device. The torque wrench is designed to prevent damage to the device from overtightening a setscrew. Other torque wrenches (for example, a blue-handled or right-angled torque wrench) have torque capabilities greater than the lead connector can tolerate.

Lead connection – Consider the following information when connecting the lead to the device:

• Cap abandoned leads to avoid transmitting electrical signals.

• Plug any unused lead ports to protect the device.

• Verify lead connections. Loose lead connections may result in inappropriate sensing and failure to deliver arrhythmia therapy.

Lead impedance – Consider the following information about lead impedance when evaluating the lead system:

• Ensure that the defibrillation lead impedance is greater than 20 Ω. An impedance of less than 20 Ω may damage the device or prevent the delivery of high-voltage therapy.

• Before taking electrical or defibrillation efficacy measurements, move objects made from conductive materials, such as guide wires, away from all electrodes. Metal objects, such as guide wires, can short circuit a device and a lead, causing electrical current to bypass the heart and possibly damage the device and the lead.

• If the LV pacing impedance for pacing LV1, LV2, LV3, or LV4 to RVcoil is greater than 3000 Ω and the V. Defib (RVcoil) impedance is greater than 200 Ω, then use LV EGM to assess the integrity of the LV lead.

2.5 Device operation

Warning: Leads other than SureScan leads may be used with the DTPA2Q1 device, but if leads other than

SureScan leads are used, the system is contraindicated for MRI scans. Before performing an MRI scan, refer to the MRI technical manual for additional information.

Atrial Capture Management – Atrial Capture Management feature does not adjust atrial outputs to values greater than 5.0 V or 1.0 ms. If the patient needs atrial pacing output greater than 5.0 V or 1.0 ms, manually program the atrial amplitude and the pulse width. If a lead dislodges partially or completely, Atrial Capture Management feature may not prevent loss of capture.

Atrial lead maturation – Do not program AT/AF detection to On or enable automatic atrial ATP therapies until the atrial lead has matured (approximately one month after implant). If the atrial lead dislodges and migrates to the ventricle, the device could inappropriately detect AT/AF, deliver atrial ATP to the ventricle, and possibly induce a life-threatening ventricular tachyarrhythmia.

Battery depletion – Carefully monitor device longevity by checking the battery voltage and the replacement indicators. Battery depletion eventually causes the device to stop functioning.

Charge Circuit Timeout message or Charge Circuit Inactive message – Contact a Medtronic representative and replace the device immediately if the implantable device app displays a Charge Circuit Timeout message or Charge Circuit Inactive message. If these messages are displayed, high-voltage therapies are not available for the patient.

Concurrent pacemaker use – If a separate pacemaker is used concurrently with the device, verify that the device does not sense the output pulses of the pacemaker. Sensing the output pulses of the pacemaker can affect the detection of tachyarrhythmias. Program the pacemaker to deliver pacing pulses at intervals longer than the tachyarrhythmia detection intervals.

Concurrent devices – Output pulses, especially from unipolar devices, may adversely affect device sensing capabilities. If a patient requires a separate stimulation device, either permanent or temporary, allow enough space between the leads of the separate systems to avoid interference in the sensing capabilities of the devices. Previously implanted pulse generators and implantable cardioverter defibrillators should generally be explanted.

Device status indicators – If any of the device status indicators (for example, device reset) are displayed on the implantable device app after interrogating the device, inform a Medtronic representative immediately. If these device status indicators are displayed, therapies may not be available to the patient.

Device reset – Electrical reset can be caused by exposure to temperatures below –18°C (0°F) or to strong electromagnetic fields. Advise patients to avoid strong electromagnetic fields. Observe temperature storage limits to avoid exposure of the device to cold temperatures. If a partial reset occurs, pacing resumes in the programmed mode with many of the programmed settings retained. If a full reset occurs, the device operates in VVI mode at 65 bpm. Electrical reset is indicated by a warning message that is immediately displayed on the implantable device app upon interrogation. To restore the device to its previous operation, it must be reprogrammed. Inform a Medtronic representative if your patient’s device has reset.

EOS (end of service) indicator – Replace the device immediately if the implantable device app displays an EOS indicator. The device may soon lose the ability to pace, to sense, and to deliver therapy adequately.

Defibrillation threshold testing – Changes in the patient’s condition, drug regimen, and other factors may change the defibrillation threshold, preventing the device from terminating the patient’s tachyarrhythmias postoperatively. Successful termination of ventricular fibrillation or ventricular tachycardia during the implant procedure is no assurance that tachyarrhythmias can be terminated postoperatively.

Magnets – Placing a magnet over the device suspends tachyarrhythmia detection.

PMT (pacemaker-mediated tachycardia) Intervention – Even with the PMT Intervention feature programmed

to On, PMTs may still require clinical intervention, such as device reprogramming, drug therapy, or lead evaluation.

Pacing and sensing safety margins – Lead maturation (at least one month after implant) may cause sensing amplitudes to decrease and pacing thresholds to increase, which can cause undersensing or a loss of capture. Provide an adequate safety margin when selecting values for pacing amplitude, pacing pulse width, and sensitivity parameters.

Patient safety during a wireless telemetry session – Make sure that you have selected the appropriate patient before proceeding with a wireless patient session. Maintain visual contact with the patient for the duration of the session. If you select the wrong patient and continue with the session, you may inadvertently program the patient’s device to the wrong settings.

Pediatric use – The device has not been tested specifically for pediatric use.

Phrenic nerve stimulation – Phrenic nerve stimulation may occur as a result of left ventricular pacing at higher

amplitudes. Although this condition is not life threatening, it is recommended that you test for phrenic nerve stimulation at various pacing amplitude settings with the patient in various positions. If phrenic nerve stimulation occurs with the patient, determine the minimum pacing threshold for phrenic nerve stimulation and program the pacing amplitude to a value that minimizes stimulation but provides an adequate pacing safety margin. Also, consider use of alternate left ventricular pacing vectors to alleviate phrenic nerve stimulation. If the LV Capture

Management feature is used, set the LV Maximum Adapted Amplitude to a value that minimizes phrenic nerve stimulation but provides an adequate pacing safety margin. Carefully consider the relative risks of phrenic nerve stimulation versus loss of capture before programming lower pacing amplitudes for the patient.

Rate control – Decisions regarding rate control should not be based on the ability of the device to prevent atrial arrhythmias.

Rate-responsive modes – Do not program rate-responsive modes for patients who cannot tolerate rates above the programmed Lower Rate. Rate-responsive modes may cause discomfort for those patients.

Right ventricular apical pacing – Right ventricular apical pacing may be associated with an increased risk of atrial fibrillation, left ventricular dysfunction, and congestive heart failure.

RV Capture Management – The RV Capture Management feature does not program right ventricular outputs to values greater than 5.0 V or 1.0 ms. If the patient needs right ventricular pacing output greater than 5.0 V or 1.0 ms, manually program right ventricular amplitude and pulse width. If a lead dislodges partially or completely, the RV Capture Management feature may not prevent loss of capture.

Sensitivity setting – Carefully evaluate the possibility of increased susceptibility to EMI and oversensing before changing the sensitivity threshold to its minimum (most sensitive) setting of 0.15 mV.

Shipping values – Do not use shipping values or nominal values for pacing amplitude and sensitivity without verifying that the values provide adequate safety margins for the patient.

Single chamber atrial modes – Do not program single chamber atrial modes for patients with impaired AV nodal conduction. Ventricular pacing does not occur in these modes.

Slow retrograde conduction and PMT – Slow retrograde conduction may induce pacemaker-mediated tachycardia (PMT) when the VA conduction time is greater than 400 ms. Programming PMT Intervention can help prevent PMT only when the VA conduction time is less than 400 ms.

Testing for cross-stimulation – At implant, and regularly when atrial ATP therapy is enabled, conduct testing at the programmed atrial ATP output settings to ensure that ventricular capture does not occur. Testing for cross-stimulation is particularly important when the lead is placed in the inferior atrium.

Twiddler’s syndrome – Twiddler’s syndrome, the tendency of some patients to manipulate their device after implant, may cause the pacing rate to increase temporarily if the device is programmed to a rate-responsive mode.

2.5.1 Pacemaker-dependent patients

Ventricular Safety Pacing – Always program Ventricular Safety Pacing (VSP) to On for pacemaker-dependent

patients. Ventricular Safety Pacing prevents ventricular asystole due to inappropriate inhibition of ventricular pacing caused by oversensing in the ventricle.

ODO pacing mode – Pacing is disabled under ODO pacing mode. Do not program the ODO mode for pacemaker-dependent patients. Instead, use the Underlying Rhythm Test to provide a brief period without pacing support.

Underlying Rhythm Test – Use caution when using the Underlying Rhythm Test to inhibit pacing. The patient is without pacing support when pacing is inhibited.

2.6 Potential adverse events

The potential adverse events associated with the use of transvenous leads and pacing systems include, but are not limited to, the following events:

• Allergic reaction

• Atrial fibrillation

• Bradyarrhythmia

• Cardiac arrest

• Device migration

• Discomfort

• Dizziness

• Dyspnea

• Erosion

• Excessive fibrotic tissue growth

• Heart failure

• Hematoma

• Hemorrhage

• Inability to deliver therapy

• Inappropriate shock

• Infection

• Lead migration/dislodgement

• Lethargy

• Loss of CRT

• Loss of pacing

• Mental anguish

• Necrosis

• Nerve damage

• Oversensing

• Palpitations

• Seroma

• Syncope

• Tachyarrhythmia

• Tissue damage due to heating of device

• Undersensing

• Wound dehiscence

3 Clinical data

3.1 Adverse events and clinical trial data

Information regarding clinical studies and adverse events related to this device is available at www.medtronic.com/manuals.

The following clinical studies are related to this device:

AdaptivCRT (Adaptive Cardiac Resynchronization Therapy) clinical study – This clinical study evaluated the safety and efficacy of the AdaptivCRT algorithm to provide patient-specific selection of LV or BiV CRT pacing as well as dynamic adjustment of AV and VV delays based on periodic automatic evaluation of intrinsic electrical conduction.

BLOCK HF clinical study – The Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block Clinical Study investigated the safety and efficacy of biventricular pacing compared to right ventricular pacing. This study provides support for biventricular pacing in Cobalt XT HF Quad CRT-D MRI SureScan Model DTPA2Q1 devices.

Cardiac Resynchronization Therapy Efficacy Enhancements (CRTee) Trial – This clinical study, which evaluated the safety and efficacy of the EffectivCRT During AF feature, provides support for this feature in the Cobalt XT HF Quad CRT-D MRI SureScan Model DTPA2Q1 devices.

Evera MRI SureScan defibrillation system clinical study – This clinical study, which evaluated the safety and efficacy of the Evera MRI SureScan defibrillation system in the clinical magnetic resonance imaging (MRI) environment, provides support for the MRI SureScan feature.

Jewel AF clinical study for AF patients only – This clinical study evaluated the atrial tachyarrhythmia therapies and dual chamber tachyarrhythmia detection algorithm provided by Jewel AF Model 7250 devices. The patients included in the study had a primary indication of atrial fibrillation or atrial flutter. It provides support for atrial

tachyarrhythmia therapies and dual chamber tachyarrhythmia detection in the Cobalt XT HF Quad CRT-D MRI SureScan Model DTPA2Q1 devices.

Jewel AF clinical study for VT/AT patients – This clinical study evaluated the atrial tachyarrhythmia therapies and dual chamber tachyarrhythmia detection algorithm provided by Jewel AF Model 7250 devices. The patients included in the study had a primary indication of ventricular tachyarrhythmia. Some of the patients in the study also had a history of atrial tachyarrhythmia. This clinical study provides support for atrial tachyarrhythmia therapies and dual chamber tachyarrhythmia detection in the Cobalt XT HF Quad CRT-D MRI SureScan Model DTPA2Q1 devices.

OptiVol Alert Performance – The prospective Optilink HF clinical study evaluated the application of fluid status telemedicine alerts for heart failure patients, and a retrospective evaluation correlated the OptiVol Alert criteria with heart failure events collected from various clinical trials of ICD or CRT-D devices with the OptiVol alert feature.

Protecta detection performance – This retrospective evaluation was performed using human rhythms collected from various clinical trials and provides support that the addition of multiple therapy discriminators in the Protecta products do not affect the overall detection performance of the Cobalt XT HF Quad CRT-D MRI SureScan Model DTPA2Q1 devices.

Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) and Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT) – These clinical studies, which

evaluated cardiac resynchronization therapy in mildly (REVERSE and RAFT) symptomatic and moderately symptomatic (RAFT) heart failure patients, provide support for Cobalt XT HF Quad CRT-D MRI SureScan Model DTPA2Q1 devices in these patients.

RV Lead Integrity Alert Performance retrospective evaluation for non-Medtronic leads – This retrospective evaluation assessed the performance of the RV Lead Integrity Alert feature when used with a St. Jude Riata/Durata lead or Boston Scientific Endotak lead. This evaluation provides information regarding the performance of the RV Lead Integrity Alert feature in these non-Medtronic lead families.

RV Lead Noise Discrimination VF detection performance – This retrospective evaluation was conducted using spontaneous rhythms and provides support that the RV Lead Noise Discrimination algorithm does not impact time to detection in Cobalt XT HF Quad CRT-D MRI SureScan Model DTPA2Q1 devices.

TWave Discrimination VF detection performance – This retrospective evaluation was conducted using induced rhythms and provides support that the TWave Discrimination algorithm does not impact time to detection in Cobalt XT HF Quad CRT-D MRI SureScan Model DTPA2Q1 devices.

Universal Antitachycardia Pacing (UATP) 2.0 Download Study – The UATP 2.0 feasibility study was a chronic, prospective, non-randomized, multicenter study designed to assess the performance of the Intrinsic ATP algorithm in patients implanted with a Medtronic specified device for approved indications, with a functional atrial lead. The Intrinsic ATP algorithm was designed to reduce ICD shocks by pace-terminating monomorphic ventricular tachycardia (MVT) using cardiac history, VT characteristics and previous ATP attempts to automatically optimize the parameters of the therapy.

Note: There are no randomized clinical trial data for this device that demonstrate programming dual cathode LV pacing has a positive impact on LV pacing response.

4 Implant procedure

4.1 Preparing for an implant

To retain the ability to safely scan the SureScan defibrillation system during MRI scans, the MRI conditions for use in Section 1.5 must be followed. Refer to the MRI technical manual for additional information.

The following implant procedures are provided for reference only. Proper surgical procedures and sterile techniques are the responsibility of the physician. Each physician must apply the information in these procedures according to professional medical training and experience.

For information about replacing a previously implanted device, see Section 4.8, Replacing a device, page 27.

Ensure that you have all of the necessary instruments, system components, and sterile accessories to perform the implant.

4.1.1 Instruments, components, and accessories required for an implant

The following non-implanted instruments are used to support the implant procedure:

• Medtronic device manager

• External defibrillator

The following sterile system components and accessories are used to perform the implant:

• Implantable device and lead system components

• Pacing system analyzer cables

• Lead introducers appropriate for the lead system

• Extra stylets of appropriate length and shape

4.1.2 Setting up and starting the device manager

Set up the device manager using the instructions for use provided with the system. Establish telemetry with the device and start a patient session.

4.1.3 Considerations for preparing for an implant

Review the following information before implanting the leads or device:

Warning: Leads other than SureScan leads may be used with the Model DTPA2Q1 device, but if leads other than SureScan leads are used, the system is contraindicated for MRI scans. Before performing an MRI scan, refer to the MRI technical manual for additional information.

Warning: Do not allow the patient to have contact with grounded electrical equipment that might produce electrical current leakage during implant. Electrical current leakage may induce tachyarrhythmias that may result in the patient’s death.

Warning: Keep external defibrillation equipment nearby for immediate use during acute lead system testing, the implant procedure, or whenever arrhythmias are possible or intentionally induced during postimplant testing.

Caution: The device is intended for implant in the pectoral region with Medtronic transvenous defibrillation leads. Implanting the device outside of the pectoral region may adversely affect the results of the OptiVol fluid measurements. No claims of safety and performance can be made with regard to other acutely or chronically implanted lead systems that are not manufactured by Medtronic.

Caution: Lead coils and Active Can electrodes that are in contact during a high-voltage therapy may cause electrical current to bypass the heart, possibly damaging the device and leads. While the device is connected to the leads, verify that therapeutic electrodes, stylets, or guide wires are not touching or connected by any material that may conduct electricity. Move objects made from conductive materials (for example, an implanted guide wire) well away from all electrodes before delivering a high-voltage shock.

Caution: Do not implant the device after the “Use by” date on the package label. Battery longevity could be reduced.

Caution: Do not immerse the device in fluid or flush the connector ports at the time of implant. Doing so could adversely affect the performance of the device and lead system.

4.1.4 How to prepare the device for implant

Before opening the sterile package, perform the following steps to prepare the device for implant:

1. Interrogate the device and create an Initial Interrogation Report. Caution: If the implantable device app reports that a device reset occurred, do not implant the device. Contact a Medtronic representative.

2. To confirm that the device is acceptable for implant, check the status of the REMAINING LONGEVITY estimate on the Quick Look screen. The REMAINING LONGEVITY estimate graphic is gray if the battery status is not acceptable for implant and it is green if the battery status is acceptable for implant. If the device has been exposed to low temperatures, the battery voltage can be temporarily lower and the charge time can increase. If the battery status is unacceptable, store the device at room temperature for 48 hours and check the battery status again to determine if the device is acceptable for implant. If an acceptable battery status cannot be obtained after 48 hours, contact a Medtronic representative. Note: If the REMAINING LONGEVITY estimate graphic on the Quick Look screen is gray, indicating that the battery status is unacceptable, do not charge the capacitors.

3. On the implantable device app, set the Time Zone for the internal clock of the device.

4. Program the therapy and pacing parameters to values appropriate for the patient. Ensure that tachyarrhythmia detection is not programmed to On.

Notes:

• Do not enable a pacing feature that affects the pacing rate (for example, Ventricular Rate Stabilization) before implanting the device. Taking this action can cause a pacing rate that is faster than expected.

• Patient information typically is entered at the time of initial implant, and it can be revised at any time.

4.2 Selecting and implanting the leads

Use the guidelines in this section to select leads that are compatible with the device. The appropriate techniques for implanting the leads may vary according to physician preference and the patient’s anatomy or physical condition. Consult the technical manuals supplied with the leads for specific implant instructions.

A complete SureScan defibrillation system is required for use in the MR environment. Before performing an MRI scan, refer to the MRI technical manual for MRI-specific warnings and precautions.

A complete SureScan defibrillation system includes the following components:

• The Model DTPA2Q1 device

• A SureScan right atrial pacing lead or a Model 6725 pin plug for the right atrial port

• A SureScan left ventricular pacing lead

• A SureScan defibrillation lead Note: When a single coil SureScan defibrillation lead is used, a Medtronic DF-1 pin plug must be secured in the SVC port to make a complete SureScan defibrillation system.

4.2.1 Selecting the leads

The device typically is implanted with the following leads:

• 1 quadripolar transvenous lead with an IS4-LLLL connector in the left ventricle (LV) for pacing.

• 1 quadripolar/tripolar transvenous lead with a trifurcated/bifurcated connector in the right ventricle (RV) for sensing, pacing, and cardioversion/defibrillation therapies.

• 1 bipolar transvenous lead with an IS-1 connector in the atrium (A) for sensing and pacing. Use of a bipolar atrial lead with ring and tip electrodes spaced ≤10 mm apart to reduce far-field R-wave sensing is recommended.

4.2.2 How to verify lead and connector compatibility

Warning: Verify lead and connector compatibility before using a lead with this device. Using an incompatible lead

may damage the connector, resulting in electrical current leakage or resulting in an intermittent electrical connection.

Note: Medtronic 3.2 mm low-profile leads are not directly compatible with the device IS-1 connector port.

Warning: Lead adaptors compromise the ability to safely perform an MRI scan on the SureScan defibrillation

system in the future. Devices connected with lead adaptors are contraindicated for an MRI scan. Refer to the MRI technical manual for additional information.

Note: Using a lead adaptor may affect the accuracy of OptiVol fluid measurements.

Note: If you are using a lead that requires an adaptor for this device, contact your Medtronic representative for

information about compatible lead adaptors.

Use the information in Table 1 to select a compatible lead.

Table 1. Lead and connector compatibility

Connector port (electrodes) Primary lead

RV (RVcoil) DF-1

LV (LV1, LV2, LV3, LV4) IS4-LLLLb quadripolar

RV (RVtip, RVring) IS-1c bipolar

A (Atip, Aring) IS-1c bipolar

SVC (SVC coil) DF-1

DF-1 refers to the international standard ISO 11318.

IS4-LLLL refers to the international standard ISO 27186, where the lead connector contacts are defined as low

voltage (L).

IS-1 refers to the international standard ISO 5841-3.

4.2.3 Implanting the leads

Implant the leads according to the instructions in the technical manuals supplied with the leads unless suitable chronic leads are already in place.

Warning: Pinching the lead can damage the lead conductor or the insulation, which may cause unwanted high-voltage therapies or the loss of sensing or pacing therapy.

Transvenous leads – If you use a subclavian approach to implant a transvenous lead, position the lead laterally to avoid pinching the lead body between the clavicle and the first rib.

The venous access site should be chosen based on physician discretion after evaluating multiple factors. Consider using the subclavian vein and the cephalic vein to separate the entry location in order to avoid implanting LV, atrial, and RV leads in the same venous access site.

LV leads – Due to the variability of cardiac venous systems, assess the venous anatomy before implanting the LV lead to determine an optimal LV lead position. Before placing a lead in the coronary sinus, obtain a venogram.

4.3 Testing the lead system

After the leads are implanted, test the lead system to verify that the sensing and pacing values are acceptable. Refer to the analyzer instructions for use.

Note: Do not measure the intracardiac EGM that is telemetered from the device to assess sensing.

Note: The measured pacing lead impedance is a reflection of measuring equipment and lead technology. Refer

to the lead technical manual for acceptable impedance values.

Bipolar leads – When measuring sensing and pacing values, measure between the tip (cathode) and ring (anode) of each bipolar pacing/sensing lead.

Lead positioning – Final lead positioning should attempt to optimize cardiac resynchronization.

Extracardiac stimulation – When pacing at 10 V using an external pacing device, test for extracardiac

stimulation from the LV lead. If extracardiac stimulation is present, consider repositioning the lead.

4.3.1 How to verify and save the sensing and pacing values

Medtronic recommends that you use a Medtronic analyzer to perform sensing and pacing measurements. When the analyzer and the device sessions are running concurrently, you can export the saved lead measurements from the analyzer session into the patient information parameters in the device session. Refer to the analyzer instructions for use for detailed procedures about performing the lead measurements.

Note: If you perform the lead measurements using an implant support instrument other than a Medtronic analyzer, enter the measurements in the device session manually.

Note: The intracardiac EGM that is telemetered from the device cannot be used to assess sensing directly.

To perform lead measurements using the device manager, take the following actions:

1. From the device manager app, start an analyzer session.

2. Measure the EGM amplitude and capture threshold using the analyzer.

3. Use the information in Table 2 to verify that the measured values are acceptable.

Note: The measured pacing lead impedance reflects the measuring equipment and lead technology. Refer to the lead technical manual for acceptable impedance values and for additional information about sensing and pacing values.

4. Select the type of lead you are testing and save the measurements.

5. Select the saved measurements that you want to export. You can select a single measurement for each lead type. Note: The selected measurements are exported to the IMPLANT window, which is accessible from the PATIENT INFORMATION screen in the device session.

6. Program the imported values into the device memory.

Table 2. Acceptable sensing and pacing values

Measurements required Acute transvenous leads Chronic leads

P-wave EGM amplitude (atrial) ≥2 mV ≥1 mV

R-wave EGM amplitude (RV) ≥5 mV ≥3 mV

LV EGM amplitude (LV to RVring

≥4 mV ≥1 mV

or LV to RVcoil)

Capture threshold (0.5 ms pulse width)

≤1.5 V (atrial) ≤3.0 V (atrial)

≤1.0 V (RV) ≤3.0 V (RV)

≤3.0 V (LV) ≤4.0 V (LV)

Chronic leads are leads that are implanted for 30 days or more.

4.4 Connecting the leads to the device

The following procedure describes how to connect the lead to the device, how to confirm that the lead connector is fully inserted in the connector block, and how to verify that the lead connection is secure.

Warning: After connecting the leads, verify that the lead connections are secure by gently tugging on each lead.

1a 1b

A loose lead connection may result in inappropriate sensing, which can cause inappropriate arrhythmia therapy or a failure to deliver arrhythmia therapy.

Caution: Use only the torque wrench supplied with the device. The torque wrench is designed to prevent damage to the device from overtightening a setscrew. Other torque wrenches (for example, a blue-handled or right-angled torque wrench) have torque capabilities greater than the lead connector can tolerate.

Caution: If you are not implanting an atrial lead, insert a Model 6725 pin plug into the atrial port to prevent electrical leakage.

See Figure 1 for information about the lead connector ports on the device.

Figure 1. Lead connector ports

1 DF-1 connector port, SVC 2 DF-1 connector port, RV 3 Device Active Can electrode

4.4.1 How to connect a lead to the device

1. Insert the torque wrench into the appropriate setscrew.

a. If the setscrew obstructs the port, retract the setscrew by turning it counterclockwise until the port is clear

(see Figure 2). Do not remove the setscrew from the connector block.

b. Leave the torque wrench in the setscrew until the lead connection is secure to allow a pathway for venting

trapped air when the lead connector is inserted into the connector port (see Figure 2).

Figure 2. Inserting the torque wrench into the setscrew

4 IS4 connector port, LV 5 IS-1 connector port, RV 6 IS-1 connector port, A

2. Insert the lead connector or pin plug into the connector port, keeping twisting to a minimum. Insert the lead connector until the lead connector pin is clearly visible in the pin viewing area. If necessary, sterile water may be used as a lubricant. No sealant is required.

3. Confirm that the lead is fully inserted into the connector pin cavity by viewing the device connector block from the side or end.

a. For the DF-1 connector port (RV), the lead connector pin is visible in the pin viewing area when the pin is

fully inserted into the connector port (see Figure 3).

b. For the IS4–LLLL connector port (LV), the band on the tip of the lead connector pin is visible in the pin

viewing area when the pin is fully inserted into the connector port (see Figure 3).

Figure 3. Confirming the lead connection (DF-1 and IS4-LLLL connectors)

4. Confirm that the lead is fully inserted into the connector pin cavity by viewing the device connector block from the side or end.

a. For the IS-1 connector port, the lead connector pin should be clearly visible beyond the setscrew block

(see Figure 4).

b. For the IS-1 connector port, the lead connector ring should be completely inside the spring contact block.

There is no setscrew in this location (see Figure 4).

Figure 4. Confirming the lead connection (IS-1 connectors)

5. Tighten the setscrew by turning it clockwise until the torque wrench clicks. Remove the torque wrench.

6. Gently tug on the lead to confirm a secure fit. Do not pull on the lead until the setscrew has been tightened.

7. Repeat these steps for each lead.

4.5 Performing ventricular defibrillation threshold tests

You can test the operation of ventricular defibrillation and the effectiveness of the implanted lead system by using either the T-Shock method or the 50 Hz Burst method to induce VF. You can then use the programmed automatic therapies to detect and treat the VF. Use your preferred method to verify that you have established adequate safety margins for sensing and defibrillation.

Carefully consider the use of VF to test the operation of ventricular defibrillation and the effectiveness of the implanted lead system. Use your discretion to decide whether to test or how to test for an adequate safety margin.

4.5.1 High-voltage implant values

See Table 3 for information about the measured high-voltage therapy values that are recommended at implant.

Table 3. High-voltage (HV) therapy values recommended at implant

Measurement Acute or chronic leads

HV delivery pathway impedance 20–200 Ω

Defibrillation threshold ≤25 J

4.5.2 How to prepare for defibrillation threshold testing

Warning: Keep external defibrillation equipment nearby for immediate use. Potentially harmful spontaneous or

induced tachyarrhythmias may occur during device testing, implant procedures, and post-implant testing.

1. Establish telemetry between the patient connector and the device.

2. Program the Active Can/SVC Coil parameter to On or Off, as appropriate for the patient.

3. Observe the markers on the Live Rhythm Monitor to verify that the device is sensing properly.

4. Perform a manual Lead Impedance Test to verify defibrillation lead connections. For information about acceptable impedance values, see Table 3 and refer to the lead technical manual. Perform this test with the device in the surgical pocket. Keep the surgical pocket very moist. If the lead impedance is out of range, perform one or more of the following tasks:

• Recheck the lead connections and lead electrode placement.

• Inspect the EGM for abnormalities.

• Repeat the manual Lead Impedance Test.

For instructions on performing defibrillation threshold testing using T-Shock and 50 Hz Burst, refer to the implantable device app help.

4.6 Positioning and securing the device

Caution: Program tachyarrhythmia detection to Off or Monitor to avoid inappropriate detection or therapy delivery

while closing the surgical pocket.

Note: Implant the device within 4 cm (1.6 in) of the surface of the skin to optimize the ability to connect to a wireless monitor.

Note: Implant the device with the engraved Medtronic logo side facing toward the skin to optimize the system performance. In addition, this orientation utilizes the PhysioCurve design to enhance patient comfort.

4.6.1 How to position and secure the device

1. Verify that each lead connector pin is fully inserted into the connector port and that all setscrews are tight.

2. To prevent twisting of the lead body, rotate the device to loosely wrap the excess lead length (see Figure 5). Do not kink the lead body.

Figure 5. Rotating the device to wrap the leads

3. Place the device and the leads into the surgical pocket with the engraved Medtronic logo side facing toward the skin.

4. Use nonabsorbable sutures to secure the device within the pocket and minimize post-implant rotation and migration. Use a surgical needle to penetrate the suture holes on the device (see Figure 6).

Figure 6. Locating the suture holes

5. Suture the pocket incision closed.

4.7 Completing the implant procedure

Warning: Do not program the Other 1:1 SVTs feature to On until the atrial lead has matured (approximately 1

month after implant). If the atrial lead dislodges and migrates to the ventricle, the Other 1:1 SVTs feature could inappropriately withhold detection and therapy.

Warning: Do not program AT/AF DETECTION to On or enable automatic atrial ATP therapies until the atrial lead has matured (approximately 1 month after implant). If the atrial lead dislodges and migrates to the ventricle, the device could inappropriately detect AT/AF, deliver atrial ATP to the ventricle, and possibly induce a life-threatening ventricular tachyarrhythmia.

4.7.1 How to complete programming the device

1. Enable tachyarrhythmia detection and the desired tachyarrhythmia therapies.

2. Perform a final VF induction, and allow the implanted system to detect and treat the tachyarrhythmia.

3. Verify that the pacing, detection, and therapy parameters are programmed to values that are appropriate for the patient. Note: Ensure the Active Can/SVC Coil parameter is programmed to SVC Off when a single coil is present.

4. Enter the patient’s information. Note: Use the PATIENT INFORMATION screen to enter complete information about the implanted leads. Use the MRI SureScan SYSTEM/OTHER HARDWARE window to enter complete information about other hardware implanted in the patient, including abandoned devices or leads, and lead extenders or adaptors. This information will be used in the future if the patient needs to be evaluated for an MRI scan. For more information, see the reference manual.

5. Configure the Medtronic CareAlert feature.

6. Program the Data Collection Setup parameters. For more information about programming the device, see the implantable device app help.

4.7.2 How to assess the performance of the device and the leads

After implanting the device, x-ray the patient as soon as possible to verify device and lead placement. Before the patient is discharged from the hospital, assess the performance of the implanted device and leads.

1. Monitor the patient’s electrocardiogram until the patient is discharged. If a lead dislodges, it usually occurs during the immediate postoperative period.

2. If any tachyarrhythmia therapies are enabled while the patient is in the hospital, interrogate the device after any spontaneous episodes to evaluate the detection and therapy parameter settings.

3. If the patient has not experienced spontaneous episodes, you may induce tachyarrhythmias using the non-invasive EP study features to further assess the performance of the system.

4. Check the pacing and sensing values, and adjust the values if necessary.

5. Demonstrate the alert tones.

6. Interrogate the device and create a Final Report to document the postoperative programmed device status.

4.8 Replacing a device

To retain the ability to safely scan the SureScan defibrillation system during future MRI scans, refer to the MRI technical manual for additional information.

Warning: Leads other than SureScan leads may be used with the Model DTPA2Q1 device, but if leads other than

SureScan leads are used, the system is contraindicated for MRI scans. Before performing an MRI scan, refer to the MRI technical manual for additional information.

Warning: Abandoned leads or previously implanted non-MRI labeled leads compromise the ability to safely scan the SureScan defibrillation system during future MRI scans. When implanting a SureScan defibrillation system, consider the risks associated with removing previously implanted leads before removing the leads to maintain the ability to safely scan the SureScan defibrillation system.

Warning: Keep external defibrillation and pacing equipment nearby for immediate use. The patient does not receive defibrillation or pacing therapy from the device when the lead is disconnected.

Caution: Disable tachyarrhythmia detection to avoid inappropriate therapy delivery while explanting the device.

Note: To meet the implant requirements, you may need to reposition or replace the chronic leads, or add an

additional high-voltage electrode.

Note: If the patient has a chronic LV lead that is not compatible with the IS4-LLLL connector port, you may need to replace the lead. Contact your Medtronic representative for information about compatible leads and devices.

Note: Any unused leads that remain implanted must be capped with a lead pin cap to avoid transmitting electrical signals. Any capped or unused leads are considered abandoned leads in the MRI conditions for use, and their presence will contraindicate the system for MRI scanning. Contact your Medtronic representative for information about lead pin caps.

4.8.1 How to explant and replace a device

1. Disable tachyarrhythmia detection to avoid potential inappropriate shocks to the patient or the implanter while explanting the device.

2. Program the device to a mode that is not rate responsive to avoid potential rate increases while explanting the device.

3. Dissect the leads and the device free from the surgical pocket. Do not nick or breach the lead insulation.

4. Use a torque wrench to loosen the setscrews in the connector block.

5. Gently pull the leads out of the connector ports.

6. Evaluate the condition of each lead (see Section 4.3, Testing the lead system, page 21). Replace a lead if the electrical integrity is not acceptable or if the lead connector pin is pitted or corroded. If you explant the lead, return it to Medtronic for analysis and disposal.

7. Connect the leads to the replacement device (see Section 4.4, Connecting the leads to the device, page 22). Note: Lead adaptors may be needed to connect the leads to the replacement device. Contact a Medtronic representative for information about compatible lead adaptors. Warning: Lead adaptors compromise the ability to safely perform an MRI scan on the SureScan defibrillation system in the future. Devices connected with lead adaptors are contraindicated for an MRI scan. Refer to the MRI technical manual for additional information.

8. Evaluate defibrillation effectiveness using the replacement device (see Section 4.5, Performing ventricular defibrillation threshold tests, page 25).

9. Position and secure the device in the surgical pocket, and suture the pocket incision closed (see Section 4.6, Positioning and securing the device, page 25).

10. Contact Medtronic for Return Mailer Kits to return explanted devices for analysis and disposal. See the back cover for addresses. Note: Disposal of explanted devices or leads is subject to local, state, and federal regulations.

5 Product specifications

5.1 Physical characteristics

Table 4. Physical characteristics

Volume

36.3 cm

Mass 83 g

H x W x D 74 mm x 51 mm x 13 mm

Surface area of device can 57 cm

Radiopaque ID

Medtronic radiopaque identifier

PLS

Table 4. Physical characteristics (continued)

Materials in contact with human tissue

Titanium, polyurethane, silicone rubber, titanium dioxide

Battery Hybrid CFx lithium/silver vanadium oxide

Volume with connector ports unplugged.

The radiopaque ID, which includes a Medtronic identifier symbol, can be viewed in a fluoroscopic image of the device.

These materials have been successfully tested for the ability to avoid biological incompatibility. The device does not produce an injurious temperature in the surrounding tissue during normal operation.

Figure 7. Connector ports and suture holes

1 DF-1 connector port, SVC 2 DF-1 connector port, RV 3 Device Active Can electrode

5 IS-1 connector port, RV 6 IS-1 connector port, A 7 Suture holes

4 IS4 connector port, LV

The Model DTPA2Q1 shield graphics are shown in Figure 8.

DF-1 refers to the international standard ISO 11318.

The IS-1 marking in Figure 8 indicates that the A and RV lead connectors conform to ISO 5841-3.

The IS4-LLLL marking in Figure 8 indicates that the LV lead connector conforms to ISO 27186.

Figure 8. Shield graphics: Model DTPA2Q1

1 A = atrial 2 RV = right ventricular 3 LV = left ventricular 4 SVC = SVC electrode

5 IS-1 marking 6 DF-1 marking 7 IS4-LLLL marking

5.2 Replacement indicators

The Remaining Longevity estimate, the replacement status, and the battery voltage appear on the implantable device app and on reports. The Recommended Replacement Time (RRT) and the End of Service (EOS) conditions are listed in Table 5.

Table 5. Replacement indicators

Recommended Replacement Time (RRT) < 2.80 V on 3 consecutive daily automatic measure-

ments

End of Service (EOS) 3 months after RRT

Remaining Longevity – The Remaining Longevity estimate displays the estimated time remaining until device RRT.

RRT (Recommended Replacement Time) – The implantable device app displays the RRT battery status to indicate that replacement of the device is recommended.

RRT date – The implantable device app displays the date when the battery reached RRT on the Quick Look and Battery and Lead Measurements screens.

EOS (End of Service) – The implantable device app displays the EOS battery status to indicate that the device should be replaced immediately and may not operate per specifications.

Replace at EOS – If the implantable device app indicates that the device is at EOS, replace the device immediately.

Prolonged Service Period – The Prolonged Service Period (PSP) is the time between the RRT and EOS. The PSP is defined as 3 months assuming the following conditions: 100% DDD pacing at 60 bpm, 2.5 V atrial and RV pacing amplitude, 3.0 V LV pacing amplitude, 0.4 ms pulse width; 600 Ω pacing load; and 6 full-energy charges. If the device exceeds these conditions, the EOS may be indicated before the end of 3 months.

5.3 Projected service life

The projected service life in years for the device is shown in Table 6. The data is based on pacing outputs programmed for the right atrium, right ventricle, and left ventricle amplitudes as specified, Pulse Widths at 0.4 ms, DDD mode, Lower Rate at 60 bpm, and atrial sensing rate at 70 bpm.

The service life projections are based on the following assumptions:

• Semi-annual maximum energy charging frequency

• A quarterly schedule of remote telemetry transmissions

• Typical shelf storage time before implant

• 1 hour of wireless telemetry during implant

• 1 hour of in-office wireless telemetry annually

Projected service life estimates are based on accelerated battery discharge data and device modeling as specified. Do not interpret these values as precise numbers.

Table 6. Projected service life

RA Ampli-

tude / Pace %

RV Ampli-

tude / Pace %

LV Ampli-

tude / Pace %

Projected service life per lead

impedance Conditions

500 Ω AdaptivCRT set

1.5 V / 0 % 2.0 V / 42% 1.75 V / 100%

10.1 years

to Bi-V and LV

RA 435 Ω / RV 430 Ω / LV 568 Ω

1.5 V / 13% 2.0 V / 42% 1.75 V / 100%

10.1 years

500 Ω

1.5 V / 100% 2.0 V / 42% 1.75 V / 100%

9.8 years

500 Ω 600 Ω

2.5 V / 15% 2.5 V / < 5% 2.5 V / 100%

9.4 years 9.7 years

2.5 V / 15% 2.5 V / 50% 2.5 V / 100% 8.8 years 9.2 years

2.5 V / 15% 2.5 V / 100% 2.5 V / 100% 8.3 years 8.7 years AdaptivCRT set to Adaptive Bi-V or set to Nonadaptive CRT

Per EN 45502-2-2 or ISO 14708-6 for RA paced percentage and lead impedance.

Based on AdaptivCRT patients with a normal PR interval.

Based on median CareLink settings for amplitude, paced percentage, and lead impedance.

Based on AdaptivCRT patients with a long PR interval.

5.3.1 Projected service life considerations

Additional full-energy charges – Each additional full-energy charge due to therapy shock or device testing

reduces projected service life by approximately 29 days.

Remote transmissions – Additional Medtronic remote transmissions reduce projected service life. At the stated conditions in Table 6, the projected service life reductions for more frequent remote transmission rates are as follows:

• Monthly transmissions over the life of the device reduce projected service life by 8.3 days, or 0.3%.

• Weekly transmissions over the life of the device reduce projected service life by 50.1 days, or 1.5%.

• Daily transmissions over the life of the device reduce projected service life by 376.9 days, or 11.9%.

• A single additional transmission reduces projected service life by approximately 0.1 days, or 0.0%.

Shelf storage time – Maximum shelf storage time of 18 months reduces projected service life by approximately

4.6%.

Pre-arrhythmia EGM storage – These projections assume that Pre-arrhythmia EGM storage is programmed to On for the lifetime of the device. Programming Pre-arrhythmia EGM storage to Off increases the projected service life of the device by approximately 2.8% or 10.4 days per year.

Wireless telemetry – Each additional hour of wireless telemetry use (in-office or implant) reduces the projected service life by approximately 1.8 days or 0.1%.

Multiple point pacing (MPP) – It is not recommended to program a dual site LV pace polarity unless there is evidence that the patient is not responding to single site LV pacing (for example, patient symptoms, quality of life, NYHA classification, electrocardiographic and/or echocardiographic evidence based on clinician judgment). Long-term programming of a dual LV polarity will affect device longevity (18% median longevity reduction). There are no randomized clinical trial data for this device that demonstrate programming dual cathode LV pacing has a positive impact on LV pacing response.

5.4 Energy levels and typical charge times

Energy levels – Stored energy is always greater than the delivered energy. Stored energy is derived from the peak

capacitor charge.

Typical charge times – The most recent capacitor charge time appears on the implantable device app and on reports. You can evaluate charge time using the Charge/Dump Test.

Table 7. Maximum energy levels and typical full energy charge times

Maximum programmed energy 40 J

Maximum delivered energy

Maximum stored energy

Typical charge time between Beginning of Service (BOS)c and Recommended Replacement Time (RRT)

Energy delivered at connector block into a 50 Ω load.

Energy stored at charge end on capacitor.

Charge time during a nonwireless telemetry session may be slightly higher.

40 J

47 J

10.5 s

Charge times per conditions specified in EN 45502-2-2 and ISO 14708-6 - Beginning of Service (BOS) is 8.9 s and Recommended Replacement Time (RRT) is 14.1 s.

5.5 Magnet application

When a magnet is placed near the device, tachyarrhythmia detection is suspended and no tachyarrhythmia therapies are delivered. Alert tones sound if programmed. Before implant and for the first 6 hours after implant, the device does not sound audible tones when a magnet is placed over the device.

Note: If the MRI SureScan mode is programmed to On, tachyarrhythmia detection and Medtronic CareAlert notifications (including audible alerts) are suspended.

5.6 Wireless specifications

Table 8.

Wireless specifications

Telemetry B (Inductive) Bluetooth

Operating Band: 150–200 kHz Operating Band: 2.4–2.4835 GHz

Maximum Output Power: −47.4 dBµA/m, measured

Maximum Output Power: −32.5 dBm EIRP

at 1 m

Interoperability compliant with Bluetooth SIG Core Specification, version 4.1

6 Device parameters

6.1 Emergency settings

Table 9. Emergency settings and default values

Parameter Selectable values

Defibrillation

Energy 0.4; 0.6 … 1.8; 2; 3 … 16; 18; 20; 22; 24; 25; 26; 28; 30;

32; 35; 40 J

Pathway

MRI SureScan Off

Cardioversion

Energy 0.4; 0.6 … 1.8; 2; 3 … 16; 18; 20; 22; 24; 25; 26; 28; 30;

Pathway

MRI SureScan Off

Fixed Burst

Interval 100; 110 … 350 … 600 ms

RV Amplitude 8.0 V

RV Pulse Width 1.5 ms

V. Pacing RV

MRI SureScan Off

VVI Pacing

V. Pacing RV

Pacing Mode VVI

Lower Rate 70 bpm

RV Amplitude

RV Pulse Width

V. Blank Post VP 240 ms

V. Rate Stabilization Off

V. Sense Response Off

MRI SureScan Off

If the Active Can/SVC Coil parameter is set to Can Off, the Active Can electrode is not used as part of the highvoltage delivery pathway. If the Active Can/SVC Coil parameter is set to SVC Off, the SVC Coil electrode is not used as part of the high-voltage delivery pathway.

If the programmed RV Amplitude is 8 V, VVI pacing is delivered at 8 V with a pulse width of 1.2 ms.

B>AX

32; 35; 40 J

B>AX

6.0 V

1.5 ms

6.2 Tachyarrhythmia detection parameters

Table 10. Tachyarrhythmia detection parameters

Parameter Programmable values Shipped Reset

AT/AF DETECTION On; Monitor Monitor Monitor

ZONES 1 ; 2 — —

AT/AF Atrial Interval

Fast AT/AF Atrial Interval

VF DETECTION

VF Detection Interval

VF Initial Beats to Detect 12/16; 18/24; 24/32; 30/40 ; 45/60;

VF Beats to Redetect 6/8; 9/12; 12/16 ; 18/24; 21/28;

FVT Enable Off ; via VF; via VT Off Off

FVT Detection Interval

VT DETECTION On; Off Off Off

VT Detection Interval

VT Initial Beats to Detect 12; 16 … 52; 76; 100 — —

VT Beats to Redetect 8; 12 … 52 — —

Monitor Monitor ; Off Off Off

VT Monitor Interval

Monitored VT Beats to Detect

PR LOGIC/WAVELET

AF/Afl

Sinus Tach

Other 1:1 SVTs On; Off Off Off

Wavelet…

Template Collected [date]

Template Evaluated [date]

Match Threshold 40; 43 …70 … 97% — —

Auto Collection Off; On — —

SVT V. Limit

150 (400); 160 (375) … 350 (171) …

— —

450 (133) ms (bpm)

150 (400); 160 (375) … 200 (300) …

— —

250 (240) ms (bpm)

On ; Off Off On

240 (250); 250 (240) … 320 (188) … 400 (150) ms (bpm)

— 320 (188) ms

(bpm)

— 30/40 60/80; 75/100; 90/120; 105/140; 120/160

— 12/16 24/32; 27/36; 30/40

200 (300); 210 (286) … 240 (250) …

— — 600 (100) ms (bpm)

280 (214); 290 (207) … 360 (167) …

— — 650 (92) ms (bpm)

280 (214); 290 (207) … 450 (133) …

— — 650 (92) ms (bpm)

16; 20 … 32 … 56; 80; 110; 130 — —

On ; Off Off Off

On ; Off; Monitor Off Off

— —

240; 250; 260 … 650 ms — —

Table 10. Tachyarrhythmia detection parameters (continued)

Parameter Programmable values Shipped Reset

OTHER ENHANCEMENTS

Stability

Off ; 30; 40 …100 ms Off Off

Onset… Off ; On; Monitor Off Off

Percent 72; 75; 78; 81 ; 84; 88; 91; 94; 97% — —

High Rate Timeout…

VF Zone Only Off ; 0.25; 0.5; 0.75; 1; 1.25; 1.5; 1.75;

Off — 2; 2.5; 3; 3.5; 4; 4.5; 5 min

All Zones Off ; 0.5; 1; 1.5 … 5; 6; 7 … 20; 22; 24;

Off Off 26; 28; 30 min

TWave On ; Off On Off

RV Lead Noise…

RV Lead Noise On ; Off; On+Timeout On Off

Timeout 0.25; 0.5; 0.75 … 2 min 0.75 min 0.75 min

The measured intervals are truncated to a 10 ms multiple (for example, 457 ms becomes 450 ms). The device uses this truncated interval value when applying the programmed criteria and calculating interval averages.

The AF/Afl, Sinus Tach, and Wavelet features are automatically set to On when VF Detection is set to On.

Date is auto-generated.

6.3 Atrial tachyarrhythmia therapy parameters

Table 11. Atrial tachyarrhythmia therapy parameters

Parameter Programmable values Shipped Reset

AT/AF PACING THERAPIES

AT/AF Rx Status On; Off Off Off

Therapy Type RX1: Ramp ; Burst+; 50 Hz

RX2: Ramp; Burst+ ; 50 Hz RX3: Ramp ; Burst+; 50 Hz

FAST AT/AF PACING THERAPIES

Fast AT/AF Rx Status On; Off Off Off

Therapy Type RX1: Ramp ; Burst+; 50 Hz

RX2: Ramp; Burst+ ; 50 Hz RX3: Ramp ; Burst+; 50 Hz

AT/AF AUTOMATIC CV

Automatic CV Status On; Off Off Off

Therapy Type CV

RX4: CV RX5: CV

Energy 0.4; 0.6 … 1.8; 2; 3 … 16; 18; 20; 22; 24;

25; 26; 28; 30; 32; 35; 40 J

Pathway

AX>B; B>AX — —

— —

Table 11. Atrial tachyarrhythmia therapy parameters (continued)

Parameter Programmable values Shipped Reset

FAST AT/AF AUTOMATIC CV

Automatic CV Status On; Off Off Off

Therapy Type CV

— — RX4: CV RX5: CV

Energy 0.4; 0.6 … 1.8; 2; 3 … 16; 18; 20; 22; 24;

— — 25; 26; 28; 30; 32; 35; 40 J

Pathway

AX>B; B>AX — —

SHARED CV

Minimum R-R Interval

Active Can/SVC Coil

400 (150); 410 (146) … 600 (100) ms (bpm)

500 (120) ms

(bpm)

Can+SVC On ; Can Off; SVC Off Can+SVC On Can+SVC On

AUTOMATIC CV LIMITS

Start Time 00:00; 01:00; 02:00; 03:00 … 23:00 03:00 03:00

Delivery Window Duration 1 ; 2; 3; 4; 6; 8; 10; 12; 16; 20; 24 h 1 h 1 h

Maximum shocks per day 1 ; 2; 3; 4; 5; No Limit 1 1

EPISODE DURATION BEFORE RX

Episode Duration Before CV

0; 1; 2; 3; 4; 5; 7; 10; 15; 20; 25; 30; 40; 50 min;

6 h 6 h

1; 2; 3; 4; 5; 6 ; 12; 24; 48; 72 h; 7 d

50 Hz parameters

50 Hz Burst Duration 0.5; 1 ; 2; 3 s — —

# Sequences 1; 2 … 10 — —

Burst+ parameters

Initial #S1 Pulses 1; 2 … 11 ; 12; 13; 14; 15; 20; 25 — —

A-S1 Interval (%AA) 28; 31; 34; 38; 41 … 59; 63; 66 … 84 ;

— — 88; 91; 94; 97%

S1-S2 (%AA) Off; 28; 31; 34; 38; 41 … 59; 63; 66; 69 …

— — 81 ; 84; 88; 91; 94; 97%

S2-S3 Decrement Off; 0; 10; 20 … 80 ms — —

Interval Decrement 0; 10 … 40 ms — —

# Sequences 1; 2 … 10 — —

Ramp parameters

Initial #S1 Pulses 1; 2 … 13 ; 14; 15; 20; 25 — —

A-S1 Interval (%AA) RX1 – RX2: 28; 31; 34; 38; 41 … 59; 63;

— — 66 … 84; 88; 91 ; 94; 97% RX3: 28; 31; 34; 38; 41 … 59; 63; 66 … 81 ; 84; 88; 94; 97%

500 (120) ms (bpm)

Table 11. Atrial tachyarrhythmia therapy parameters (continued)

Parameter Programmable values Shipped Reset

Interval Decrement 0; 10 … 40 ms — —

# Sequences 1; 2 … 10 — —

STOP ATRIAL RX AFTER (shared)

Rx/Lead Suspect…

Disable Atrial ATP if it

Yes ; No — —

accelerates V. rate?

Disable all atrial therapies

Yes ; No — —

if atrial lead position is suspect? (Atrial Lead Position Check)

Duration to Stop None; 12; 24; 48 ; 72 h 48 h 48 h

EPISODE DURATION BEFORE RX

Episode Duration Before ATP

0; 1 ; 2; 3; 4; 5; 7; 10; 15; 20; 25; 30; 40; 50 min;

1 min 1 min

1; 2; 3; 4; 5; 6; 12; 24 h

REACTIVE ATP

Rhythm Change On ; Off On On

Time Interval Off ; 2; 4; 7; 12; 24; 36; 48 h Off Off

SHARED ATRIAL ATP

A-A Minimum ATP Inter-

val

100; 110 …150 … 400 ms 150 ms 150 ms

A. Pacing Amplitude 1; 2 ; 3 … 6 ; 8 V 6 V 6 V

A. Pacing Pulse Width 0.1; 0.2 … 1.5 ms 1.5 ms 1.5 ms

VVI/VOO Backup PacingeOff; On (Always); On (Auto Enable) On (Auto Ena-

ble)

VVI/VOO Backup Pacing

60; 70 … 120 bpm 70 bpm 70 bpm

On (Auto Enable)

Rate

Nonprogrammable

The Active Can/SVC Coil parameter applies to all automatic, manual, and emergency high-voltage therapies. It also applies to T-Shock inductions.

If V. Pacing is programmed to LV, V. Backup Pacing is delivered to the LV chamber. Otherwise, V. Backup Pacing is delivered to the RV chamber.

6.4 Ventricular tachyarrhythmia therapy parameters

Table 12. Ventricular tachyarrhythmia therapy parameters

Parameter Programmable values Shipped Reset

VF THERAPIES

VF Therapy Status On ; Off On On

Energy RX1–RX2: 0.4; 0.6 … 1.8; 2; 3 … 16; 18;

20; 22; 24; 25; 26; 28; 30; 32; 35; 40 J RX3–RX6: 10; 11 … 16; 18; 20; 22; 24; 25; 26; 28; 30; 32; 35; 40 J

Pathway

AX>B; B>AX RX1–RX4: B>AX RX5–RX6: AX>B

VF ATP

Therapy Status On ; Off On Off

Therapy Type Ramp; Burst; Ramp+; iATP — —

Deliver ATP if last 8 R-R >= 200; 210 … 240 … 300 ms — —

# Sequences Before Charging

Ramp, Burst, Ramp+: 0 ; 1

iATP: 1; 2 ; 3

# Sequences During Charg-

1 — —

ing

S2/S3 Minimum iATP:

150; 160 ; 170; 180 ms

Initial # Pulses Ramp:

1; 2 … 6 … 15

Burst: 1; 2 … 8 … 15

Ramp+: 1; 2; 3 … 15

R-S1 Interval=(%RR) Ramp:

50; 53; 56; 59; 63; 66 … 84; 88; 91 ; 94; 97%

Burst: 50; 53; 56; 59; 63; 66 … 84; 88 ; 91; 94; 97%

Ramp+: 50; 53; 56; 59; 63; 66; 69; 72; 75 ; 78; 81; 84; 88; 91; 94; 97%

Interval Dec Ramp, Burst:

0; 10 … 40 ms

ChargeSaver

Smart Mode

On ; Off On —

40 J 40 J

B>AX B>AX

— —

Table 12. Ventricular tachyarrhythmia therapy parameters (continued)

Parameter Programmable values Shipped Reset

S1S2(Ramp+)=(%RR) 50; 53; 56; 59; 63; 66; 69 … 81; 84; 88;

91; 94; 97%

S2SN(Ramp+)=(%RR) 50; 53; 56; 59; 63; 66 ; 69 … 81; 84; 88;

91; 94; 97%

FVT THERAPIES / VT THERAPIES

FVT Therapy Status On; Off Off Off

VT Therapy Status On; Off Off Off

Therapy Type

d,e

CV; Burst; Ramp; Ramp+; iATP — —

Smart Mode RX1-RX4: On; Off — —

# Sequences iATP:

FVT therapies: 2; 3; 4; 5 …10 VT therapies: 2; 3 … 7 ; 8; 9; 10 Burst, Ramp, Ramp+: VT therapies: 1; 2; 3 …10 FVT therapies: 1 ; 2 …10

S2/S3 Minimum iATP:

150; 160 ; 170; 180 ms

Initial # Pulses Ramp:

— —

1; 2 … 6 … 15

Burst: 1; 2 … 8 … 15

Ramp+:

— —

1; 2; 3 … 15

R-S1 Interval=(%RR) Burst:

— — 50; 53; 56; 59; 63; 66 … 84; 88 ; 91; 94; 97%

Ramp: 50; 53; 56; 59; 63; 66 … 84; 88; 91 ; 94; 97%

Ramp+: 50; 53; 56; 59; 63; 66; 69; 72; 75 ; 78; 81; 84; 88; 91; 94; 97%

S1S2(Ramp+)=(%RR) 50; 53; 56; 59; 63; 66; 69 … 81; 84; 88;

91; 94; 97%

S2SN(Ramp+)=(%RR) 50; 53; 56; 59; 63; 66 ; 69 … 81; 84; 88;

91; 94; 97%

Interval Dec Burst, Ramp:

— — 0; 10 … 40 ms

Table 12. Ventricular tachyarrhythmia therapy parameters (continued)

Parameter Programmable values Shipped Reset

CV for FVT and VT therapies

Energy 0.4; 0.6 … 1.8; 2; 3 … 16; 18; 20; 22; 24;

— — 25; 26; 28; 30; 32; 35; 40 J VT RX1–RX2: 20 J VT RX3–RX6: 40 J FVT RX1–RX6: 40 J

Pathway

AX>B; B>AX

— — RX1–RX4: B>AX RX5–RX6: AX>B

SHARED V. ATP

V-V Minimum ATP Interval 150; 160 … 200 … 400 ms 200 ms 200 ms

V. Amplitude 1; 2; 3 … 6; 8 V 8 V 8 V

V. Pulse Width 0.1; 0.2 … 1.5 ms 1.5 ms 1.5 ms

V. Pace Blanking 170 ; 180; 190 … 450 ms 170 ms 170 ms

V. Pacing

f,g

RV ; LV → RV; LV RV RV

SHARED V. THERAPIES

Active Can/SVC Coil

Progressive Episode Thera-

Can+SVC On ; Can Off; SVC Off Can+SVC On Can+SVC On

On; Off Off Off

pies

Confirmation+ On ; Off On On

ChargeSaver is not available for iATP.

Smart Mode is available for RX1– RX4.

FVT therapies must be increasingly aggressive.

Last therapy that is programmed to On must be a CV.

If RV+LV is selected, the ATP therapy is delivered LV→RV with a 2.5 ms delay.

All iATP therapies will be delivered through RV pacing only.

The Active Can/SVC Coil parameter applies to all automatic, manual, and emergency high-voltage therapies. It also applies to T-Shock inductions.

6.5 Pacing parameters

Table 13.

Parameter Programmable values Shipped Reset

Mode DDDR; DDD ; AAIR<=>DDDR;

Mode Switch On ; Off On On

Lower Rate

Upper Tracking Rate 80; 85 … 130 … 175 bpm 130 bpm 130 bpm

Modes, rates, and intervals

AAI<=>DDD; DDIR; DDI; AAIR; AAI; VVIR; VVI; DOO; AOO; VOO; ODO

30; 35 … 50 ; 55; 60; 70; 75 … 150 bpm 50 bpm 65 bpm

DDD VVI

Table 13. Modes, rates, and intervals (continued)

Parameter Programmable values Shipped Reset

Paced AV

Sensed AV

30; 40 … 130 … 350 ms 130 ms 180 ms

30; 40 … 100 … 350 ms 100 ms 150 ms

PVARP Auto ; 150; 160 … 500 ms Auto Auto

Minimum PVARP 150; 160 … 250 … 500 ms 250 ms 250 ms

A. Refractory Period 150; 160 … 310 … 500 ms 310 ms 310 ms

The corresponding Lower Rate Interval can be calculated as follows: Lower Rate Interval (ms) = 60,000/Lower Rate.

If CRT is adaptive, Paced AV and Sensed AV cannot be selected or programmed.

Table 14. Atrial pacing parameters

Parameter Programmable values Shipped Reset

A. Amplitude 0.50; 0.75 …1.25; 1.50; 1.75 …3.50 …

3.50 V —

5.00; 5.50; 6.00; 8.00 V

A. Pulse Width 0.03; 0.06; 0.10; 0.20; 0.30; 0.40 …

0.40 ms —

1.50 ms

Atrial Sensitivity

Off; 0.15;0.30 ; 0.45; 0.60; 0.90; 1.20;

0.30 mV 0.30 mV

1.50; 1.80; 2.10; 4.00 mV

This setting applies to all sensing in this chamber for both tachyarrhythmia detection and bradycardia pacing operations.

Table 15. RV pacing parameters

Parameter Programmable values Shipped Reset

RV Amplitude 0.50; 0.75 … 1.25; 1.50; 1.75 … 3.50 …

3.50 V 6.00 V

5.00; 5.50; 6.00; 8.00 V

RV Pulse Width 0.03; 0.06; 0.10; 0.20; 0.30; 0.40 …

0.40 ms 1.50 ms

1.50 ms

RV Sensitivity

0.15; 0.30 ; 0.45; 0.60; 0.90; 1.20 mV 0.30 mV 0.30 mV

Pace Polarity Bipolar; Tip to Coil Bipolar Bipolar

Sense Polarity Bipolar; Tip to Coil Bipolar Bipolar

This setting applies to all sensing in this chamber for both tachyarrhythmia detection and bradycardia pacing operations.

Table 16. LV parameters

Parameter Programmable values Shipped Reset

LV Amplitude 0.50; 0.75 … 1.25; 1.50; 1.75 … 3.50 …

3.50 V —

5.00; 5.50; 6.00; 8.00 V

LV Pulse Width 0.03; 0.06; 0.10; 0.20; 0.30; 0.40 …

0.40 ms 1.50 ms

1.50 ms

LV Pace Polarity LV1 to LV2; LV1 to RVcoil; LV1 to LV3; LV1

LV1 to LV2 LV1 to LV2 to LV4; LV2 to LV1; LV2 to RVcoil; LV2 to LV3; LV2 to LV4; LV3 to RVcoil; LV3 to LV1; LV3 to LV2; LV3 to LV4; LV4 to RVcoil; LV4 to LV1; LV4 to LV2; LV4 to LV3

Table 17. 2nd LV pacing parameters

Parameter Programmable values Shipped Reset

2ND LV Amplitude 0.50; 0.75 … 1.25; 1.50; 1.75 … 3.50 …

— —

5.00; 5.50; 6.00; 8.00 V

2ND LV Pulse Width 0.03; 0.06; 0.10; 0.20; 0.30; 0.40 …

0.40 ms 0.40 ms

1.50 ms

2ND LV Pace Polarity LV1 to RVcoil; LV1 to LV2; LV1 to LV3; LV1

LV4 to RVCoil LV4 to RVCoil to LV4; LV2 to RVcoil; LV2 to LV1; LV2 to LV3; LV2 to LV4; LV3 to RVcoil; LV3 to LV1; LV3 to LV2; LV3 to LV4; LV4 to RVcoil; LV4 to LV1; LV4 to LV2; LV4 to LV3

Table 18. CRT/MPP parameters

Parameter Programmable values Shipped Reset

AdaptivCRT Nonadaptive CRT; Adaptive Bi-V; Adaptive

Bi-V and LV

V. Pacing

V-V Pace Delay

RV; LV; LV→RV ; RV→LV; LV→RV RV

Auto ; 0; 10 … 80 ms Auto —

Adaptive Bi-V

and LV

Nonadaptive CRT

EffectivCRT During AF On ; Off On Off

Maximum Rate 80; 85 …110 ; 115 … 130 bpm 110 bpm —

MPP On; Off Off Off

LV-LV Pace Delay 0 ; 10 … 50 ms 0 ms 0 ms

V. Sense Response On ; Off On Off

Maximum Rate 95; 100 …130 … 150 bpm 130 bpm 130 bpm

Atrial Tracking Recovery On ; Off On Off

If CRT is set to adaptive, V. Pacing cannot be selected or programmed.

Table 19. Atrial Capture Management parameters

Parameter Programmable values Shipped Reset

Atrial Capture Management Adaptive ; Off; Monitor Adaptive Off

Atrial Amplitude Safety

1.5x ; 2.0x; 2.5x; 3.0x 1.5x —

Margin

Atrial Minimum Adapted

1.0; 1.5 ; 2.0; 2.5; 3.0; 3.5 V 1.5 V —

Amplitude

Atrial Acute Phase Remain-

Off; 30; 60; 90; 120 ; 150 days 120 days —

ing

Table 20. RV Capture Management parameters

Parameter Programmable values Shipped Reset

RV Capture Management Adaptive ; Off; Monitor Adaptive Off

RV Amplitude Safety Mar-

1.5x ; 2.0x; 2.5x; 3.0x 1.5x —

gin

RV Minimum Adapted

1.00; 1.50; 2.00 ; 2.50; 3.00; 3.50 V 2.00 V —

Amplitude

RV Acute Phase Remaining Off; 30; 60; 90; 120 ; 150 days 120 days —

Table 21. LV Capture Management parameters

Parameter Programmable values Shipped Reset

LV Capture Management Adaptive ; Off; Monitor Adaptive Off

LV Amplitude Safety Margin + 0.5; + 1.0; + 1.5; + 2.0; + 2.5 V; + Auto + Auto —

LV Maximum Adapted

0.50; 0.75 … 5.00; 5.50; 6.00 V 6.00 V —

Amplitude

Table 22. 2ND LV Capture Management parameters

Parameter Programmable values Shipped Reset

2ND LV Capture Manage-

Adaptive ; Off; Monitor Adaptive Off

ment

2ND LV Amplitude Safety

+ 0.5; + 1.0; + 1.5; + 2.0; + 2.5 V; + Auto + Auto —

Margin

2ND LV Maximum Adapted

0.50; 0.75 … 5.00; 5.50; 6.00 V 6.00 V —

Amplitude

Table 23. Blanking periods

Parameter Programmable values Shipped Reset

PVAB Interval 10; 20 … 150 … 300 ms

100; 110 … 150 … 300 ms

PVAB Method Partial ; Partial+; Absolute

150 ms 150 ms

Partial Partial

Table 23. Blanking periods (continued)

Parameter Programmable values Shipped Reset

A. Blank Post AP 150; 160 … 200 … 250 ms 200 ms 240 ms

A. Blank Post AS 100 ; 110 … 170 ms 100 ms 100 ms

V. Blank Post VP 170; 180 … 230 … 450 ms 230 ms 240 ms

V. Blank Post VS 120 ; 130 … 170 ms 120 ms 120 ms

When PVAB Method = Partial+ or Absolute

When PVAB Method = Partial

Programming the PVAB method to Absolute automatically resets the interval to 30 ms. If the PVAB method is programmed to Partial or Partial+, the interval resets to 150 ms.

Table 24. Rate Response pacing parameters

Parameter Programmable values Shipped Reset

Upper Sensor Rate 80; 85 … 120 … 175 bpm 120 bpm 120 bpm

ADL Rate 60; 65 … 95 … 170 bpm 95 bpm 95 bpm

Rate Profile Optimization On ; Off On On

ADL Response 1; 2; 3 ; 4; 5 3 3

Exertion Response 1; 2; 3 ; 4; 5 3 3

Activity Threshold Low ; Medium Low; Medium High; High Low Medium Low

Activity Acceleration 15; 30 ; 60 s 30 s 30 s

Activity Deceleration Exercise ; 2.5; 5; 10 min Exercise 5 min

ADL Setpoint 5; 6 … 40; 42 … 80 18 18

UR Setpoint 15; 16 … 40; 42 … 80; 85 … 180 40 40

Table 25. Rate Adaptive AV parameters

Parameter Programmable values Shipped Reset

Rate Adaptive AV

Off; On On On

Start Rate 50; 55 … 90 … 145 bpm 90 bpm —

Stop Rate 55; 60 … 130 … 175 bpm 130 bpm —

Minimum Paced AV 30; 40 … 100 … 200 ms 100 ms 140 ms

Minimum Sensed AV 30; 40 … 70 … 200 ms 70 ms 110 ms

If CRT is adaptive, Rate Adaptive AV parameters cannot be programmed.

Table 26.

Atrial Rate Stabilization parameters

Parameter Programmable values Shipped Reset

A. Rate Stabilization On; Off Off Off

Maximum Rate 80; 85 … 100 … 150 bpm — —

Interval Percentage Incre-

12.5; 25 ; 50% — —

ment

Table 27. Atrial Preference Pacing parameters

Parameter Programmable values Shipped Reset

A. Preference Pacing On; Off Off Off

Maximum Rate 80; 85 … 100 … 150 bpm — —

Interval Decrement 30 ; 40 … 100; 150 ms — —

Search Beats 5; 10; 15; 20 ; 25; 50 — —

Table 28. Post Mode Switch Overdrive Pacing parameters

Parameter Programmable values Shipped Reset

Post Mode Switch On; Off Off Off

Overdrive Rate 70; 75; 80 … 120 bpm — —

Overdrive Duration 0.5; 1; 2; 3; 5 ; 10; 20; 30; 60; 90; 120 min — —

Table 29. Conducted AF Response parameters

Parameter Programmable values Shipped Reset

Conducted AF Response On ; Off On Off

Response Level Low; Medium ; High Medium —

Maximum Rate 80; 85 … 110 … 130 bpm 110 bpm —

Table 30. Ventricular Rate Stabilization parameters

Parameter Programmable values Shipped Reset

V. Rate Stabilization On; Off Off Off

Maximum Rate 80; 85 … 100 …120 bpm — —

Interval Increment 100; 110 … 150 … 400 ms — —

Table 31. Post VT/VF Shock Pacing parameters

Parameter Programmable values Shipped Reset

Post VT/VF Shock Pacing On; Off Off Off

Overdrive Rate 70; 75; 80 … 120 bpm — —

Overdrive Duration 0.5 ; 1; 2; 3; 5; 10; 20; 30; 60; 90; 120 min — —

Table 32. Post Shock Pacing parameters

Parameter Programmable values Shipped Reset

Post Shock A. Amplitude 1.0; 2.0; 3.0; 4.0 ; 5.0; 6.0; 8.0 V 4.0 V —

Post Shock A. Pulse Width 0.1; 0.2 … 1.5 ms 1.5 ms —

Table 32. Post Shock Pacing parameters (continued)

Parameter Programmable values Shipped Reset

Post Shock V. Amplitude

Post Shock V. Pulse Width

Applies to all ventricular chambers paced.

1.0; 2.0 … 6.0 ; 8.0 V 6.0 V 6.0 V

0.1; 0.2 … 1.5 ms 1.5 ms 1.5 ms

Table 33. Rate Drop Response parameters

Parameter Programmable values Shipped Reset

Rate Drop Response

On; Off Off Off

Detection Type Drop ; Low Rate; Both — —

Drop Size 10; 15 … 25 … 50 bpm — —

Drop Rate 30; 40 … 60 … 100 bpm — —

Detection Window 10; 15; 20; 25; 30 s

— — 1 ; 1.5; 2; 2.5 min

Detection Beats 1; 2; 3 beats — —

Intervention Rate 70; 75 … 100 … 150 bpm — —

Intervention Duration 1; 2 … 15 min — —

When Rate Drop Response is programmed to On, the Lower Rate is automatically set to 45 bpm.

Table 34. Sleep parameters

Parameter Programmable values Shipped Reset

Sleep On; Off Off Off

Sleep Rate 30; 35 … 50 ; 55; 60; 70; 75 … 100 bpm — —

Bed Time 00:00; 00:10 … 22:00 … 23:50 — —

Wake Time 00:00; 00:10 … 07:00 … 23:50 — —

Table 35. Non-Competitive Atrial Pacing (NCAP) parameters

Parameter Programmable values Shipped Reset

Non-Comp Atrial Pacing On ; Off On On

NCAP Interval 200; 250; 300 ; 350; 400 ms 300 ms 300 ms

Table 36. MRI SureScan parameters

Parameter Programmable values Shipped Reset

MRI SureScan On; Off Off Off

MRI Pacing Mode DOO (asynchronous); AOO (asynchro-

— — nous); VOO (asynchronous); ODO (off)

MRI Pacing Rate 60; 70; 75… 120 bpm — —

Table 37. Additional pacing features

Parameter Programmable values Shipped Reset

PMT Intervention On ; Off On Off

PVC Response On ; Off On On

V. Safety Pacing

Delivered as LV pacing when LV pacing is permanently programmed or the AdaptivCRT operating value is LV.

On ; Off On On

Delivered as RV pacing when RV only pacing is permanently programmed. Otherwise, delivered as Bi-V pacing.

6.6 Medtronic CareAlert parameters

Table 38. Clinical Management Alerts

Parameter Programmable values Shipped Reset

OptiVol 2.0 Fluid Settings…

DEVICE TONE and WIRELESS ALERT

OptiVol Alert Enable

DEVICE TONE Off ; On; Suspend 3 days; Sus-

pend 5 days; Suspend 7 days; Suspend 14 days

WIRELESS ALERT Off ; On Off Off

OptiVol Threshold

30; 40: 50; 60 … 180 60 60

AT/AF Burden and Rate Settings…

DEVICE TONE and WIRELESS ALERT

AT/AF Daily Burden Off ; On Off Off

Daily AT/AF Burden 0.5; 1; 2; 6 ; 12; 24 h — —

Avg. V. Rate During AT/AF Off ; On Off Off

Avg. V. Rate During AT/AF Bur-

0.5; 1; 2; 6 ; 12; 24 h — —

den Time

Avg. V. Rate during AT/AF 90; 100 … 150 bpm — —

VT/VF Episodes and Therapies…

DEVICE TONE and WIRELESS ALERT

Monitored VT Episode Detected Off ; On Off Off

THRESHOLDS 1 episode 1 episode 1 episode

Daily VT/VF Episodes Off ; On Off Off

THRESHOLDS 3 episodes/day 3 episodes/day 3 epi-

Weekly ATP Delivered Episodes Off ; On Off Off

THRESHOLDS 1 ; 2; 3; 4; 5 3 episodes/week 3 epi-

Off Off

sodes/day

sodes/week

Table 38. Clinical Management Alerts (continued)

Parameter Programmable values Shipped Reset

Number of Shocks Delivered in an Episode

THRESHOLDS

Off ; On Off Off

1 ; 2; 3; 4; 5; 6 1 1

Total VP < 90%

DEVICE TONE and WIRELESS

Off ; On

Off Off

ALERT

Alert triggered if percent of cumulative right ventricular pacing is less than 90% for 7 consecutive days.

Decreasing the OptiVol Threshold makes the device more sensitive to changes in the patient’s thoracic fluid status. Increasing the OptiVol Threshold could delay or prevent device observation of significant changes in the patient’s thoracic fluid status.

This parameter is displayed only if an associated alert has been enabled.

Note that VF, VT, and FVT therapies could be delivered during a single episode (from initial detection until episode termination).

Table 39. Lead/Device Integrity Alerts

Parameter Programmable values Shipped Reset

RV Lead…

DEVICE TONE and WIRELESS ALERT

RV Lead Integrity On ; Off On On

RV Lead Noise On ; Off On Off

Lead Impedance Out of Range…

DEVICE TONE and WIRELESS ALERT

A. Pacing ENABLE On ; Off On Off

A. Pacing LESS THAN 200 ; 300; 400; 500 Ω 200 Ω 200 Ω

A. Pacing GREATER THAN 1000; 1500; 2000; 3000 Ω 3000 Ω 3000 Ω

RV Pacing ENABLE On ; Off On On

RV Pacing LESS THAN 200 ; 300; 400; 500 Ω 200 Ω 200 Ω

RV Pacing GREATER THAN 1000; 1500; 2000; 3000 Ω 3000 Ω 3000 Ω

LV Pacing ENABLE On ; Off On Off

LV Pacing LESS THAN 200 ; 300; 400; 500 Ω 200 Ω 200 Ω

LV Pacing GREATER THAN 800; 1000; 1500; 2000; 3000 Ω 3000 Ω 3000 Ω

2ND LV Pacing ENABLE On ; Off On Off

2ND LV Pacing LESS THAN 200 ; 300; 400; 500 Ω 200 Ω 200 Ω

2ND LV Pacing GREATER

800; 1000; 1500; 2000; 3000 Ω 3000 Ω 3000 Ω

THAN

RV Defibrillation ENABLE On ; Off On On

RV Defibrillation LESS THAN 20 ; 30; 40; 50 Ω 20 Ω 20 Ω

RV Defibrillation GREATER

100; 130; 160; 200 Ω 200 Ω 200 Ω

THAN

Table 39. Lead/Device Integrity Alerts (continued)

Parameter Programmable values Shipped Reset

SVC Defibrillation ENABLE

On ; Off On On

SVC Defibrillation LESS THAN 20 ; 30; 40; 50 Ω 20 Ω 20 Ω

SVC Defibrillation GREATER

100; 130; 160; 200 Ω 200 Ω 200 Ω

THAN

Capture Management High Threshold…

DEVICE TONE and WIRELESS ALERT

A. Capture Off ; On Off Off

RV Capture Off ; On Off Off

LV Capture Off ; On Off Off

2nd LV Capture Off ; On Off Off

Low Battery Voltage RRT

DEVICE TONE and WIRELESS

On ; Off On On

ALERT

Excessive Charge Time EOS

DEVICE TONE and WIRELESS

On ; Off On On

ALERT

VF Detection Off, 3+ VF or 3+ FVT Rx Off

DEVICE TONE and WIRELESS

On ; Off On On

ALERT

If an SVC lead is not implanted, the alert will not sound.

Table 40. Shared parameters

Parameter Programmable values Shipped Reset

Wireless Telemetry with Monitor On ;Off On On

Alert Time (OptiVol)…

Alert Time (all others)…

This parameter is displayed only if an associated alert has been enabled.

The implantable device app expresses time in the 24-hour format or in the 12-hour format, depending on your

00:00; 00:10 … 10:10 … 23:50

00:00; 00:10 … 08:00 … 23:50

10:10 10:10

08:00 08:00

tablet settings.

6.7 Data collection parameters

Table 41.

Parameter Programmable values Shipped Reset

LECG Source (Leadless ECG)

LECG Range (Leadless ECG)

Data collection parameters

Can to SVC

RVcoil to Aring

±1; ±2 ; ±4; ±8; ±12; ±16; ±32 mV ±2 mV ±2 mV

d,e

; Can to Aring;

Can to SVC Can to SVC

Table 41. Data collection parameters (continued)

Parameter Programmable values Shipped Reset

EGM 1 Source RVtip to RVring; RVtip to RVcoil;

Atip to Aring Atip to Aring Atip to RVring; Atip to Aring ; Aring to RVring; Aring to RVcoil; LV3 to RVcoil; LV3 to LV4

EGM 1 Range ±1; ±2; ±4; ±8 ; ±12; ±16; ±32 mV ±8 mV ±8 mV

EGM 2 Source

Can to RVring; Can to RVcoil ; Can to LV1; Can to SVC

d,e

; RVtip to RVring;

Can to RVcoil Can to RVcoil

RVtip to RVcoil; RVtip to LV1; RVcoil to SVCd LV1 to RVcoil; LV1 to LV2; LV1 to SVCd; LV2 to RVcoil

EGM 2 Range

EGM 3 Source RVtip to RVring ; RVtip to RVcoil;

±1; ±2; ±4; ±8; ±12 ; ±16; ±32 mV ±12 mV ±12 mV

RVtip to RVring RVtip to RVring LV1 to RVring; LV1 to RVcoil; LV1 to LV2; LV1 to LV3; LV1 to LV4; LV2 to RVcoil; LV2 to LV3; LV2 to LV4; LV3 to RVcoil; LV3 to LV4; LV4 to RVcoil; Can to RVcoil

EGM 3 Range ±1; ±2; ±4; ±8 ; ±12; ±16; ±32 mV ±8 mV ±8 mV

Monitored EGM1 and EGM2; EGM1 and

EGM3 ; EGM2 and EGM3; EGM1

EGM1 and

EGM3

EGM1 and

EGM2 and LECG; EGM2 and LECG; EGM3 and LECG

Pre-arrhythmia EGM Off; On Continuous On Continuous Off

V. Sensing Episodes

COLLECT IF: Consecutive VS > =

END COLLECTION IF:

5; 8; 10 ; 15; 20; 30; 40; 50; 100; 150;

10 senses 10 senses

200 senses

2; 3 ; 5; 10 paces 3 paces 3 paces

Consecutive VP > =

Device Date/Time

(select time zone) — —

Holter Telemetry Duration Off ; 0.5; 1; 2; 4; 8; 16; 24; 36; 46 h Off Off

This EGM channel displays far-field signals. To display an approximation of a surface ECG signal, choose the Can to SVC EGM source.

Wavelet source.

Range for Wavelet source.

An SVC electrode must be present for this configuration.

If the Can to SVC source is selected, the EGM Range is automatically set to ±2 mV. The EGM Range is automatically set to ±8 mV for all other EGM Source options.

The times and dates stored in episode records and other data are determined by the Device Date/Time clock.

6.8 System test parameters

Table 42. System test parameters

Parameter Selectable values

PACING THRESHOLD test parameters

Test Type (Atrium or RV test) Amplitude; Pulse Width

Test Type (LV test) Amplitude; Pulse Width; Phrenic Nerve Stim - Amplitude;

Phrenic Nerve Stim - Pulse Width

Chamber Atrium; RV; LV

Decrement After 2; 3 … 15 pulses

RV Pace Polarity Bipolar; Tip to Coil

LV Pace Polarity LV1 to RVcoil; LV1 to LV2; LV1 to LV3; LV1 to LV4; LV2 to

RVcoil; LV2 to LV1; LV2 to LV3; LV2 to LV4; LV3 to RVcoil; LV3 to LV1; LV3 to LV2; LV3 to LV4; LV4 to RVcoil; LV4 to LV1; LV4 to LV2; LV4 to LV3

Modea (RV or LV test) VVI; VOO; DDI; DDD; DOO

Modea (Atrium test) AAI; AOO; DDI; DDD; DOO

Lower Rate

RV Amplitude 0.25; 0.50 … 5.00; 5.50; 6.00; 8.00 V

RV Pulse Width 0.03; 0.06; 0.10; 0.20 … 1.50 ms

LV Amplitude 0.25; 0.50 … 5.00; 5.50; 6.00; 8.00 V

LV Pulse Width 0.03; 0.06; 0.10; 0.20 … 1.50 ms

A. Amplitude 0.25; 0.50 … 5.00; 5.50; 6.00; 8.00 V

A. Pulse Width 0.03; 0.06; 0.10; 0.20 … 1.50 ms

AV Delay 30; 40 … 350 ms

V. Pace Blanking 150; 160 … 450 ms

A. Pace Blanking 150; 160 … 250 ms

PVARP

VectorExpress LV AUTOMATED test parameters

Pulse Width 0.40; 0.50 … 1.50 ms

TEST LV1, 2, 3, 4 to RVcoil

SENSING test parameters

Mode

AV Delay 30; 40 … 350 ms

Lower Rate

30; 35 … 60; 70; 75 … 150 bpm

150; 160 … 500 ms

LV1 to LV2, LV3, LV4 LV2 to LV1, LV3, LV4 LV3 to LV1, LV2, LV4 LV4 to LV1, LV2, LV3

DDD; DDI; AAI; VVI; ODO

30; 35 … 60; 70; 75 … 120 bpm

Table 42. System test parameters (continued)

Parameter Selectable values

CardioSync OPTIMIZATION test parameters

Sensing Lower Rate 30; 35 … 60; 70; 75 … 90 bpm

Pacing Lower Rate 35; 40 … 60; 70; 75 … 95 bpm

WAVELET test parameters

Match Threshold 40; 43 … 70 … 97%

Mode

ODO; AAI; VVI; DDD; DDI

AV Delay 30; 40 … 350 ms

Lower Rate

The selectable values for this parameter depend on the programmed pacing mode.

When performing the test in DDD mode, the Lower Rate must be less than the programmed Upper Tracking

30; 35 … 60; 70; 75 … 120 bpm

Rate.

The selectable values for this parameter depend on the programmed PVAB values.

6.9 EP Study parameters

Table 43. T-Shock parameters

Parameter Selectable values

Chamber

Resume at DELIVER Enabled ; Disabled

Enable Enabled; Disabled

#S1 2; 3; 4; 5 ; 6; 7; 8

S1S1 300; 310 … 400 … 2000 ms

Delay 20; 30 … 300 … 600 ms

Energy/Pathway

Energy 0.4; 0.6; 0.8; 1.0 … 1.8; 2; 3; 4 … 16; 18; 20; 22; 24; 25;

Pathway

Waveform Monophasic ; Biphasic

If the chamber selected is RV+LV, the delay is set to 2.5 ms with LV pace delivered first.

RV ; LV; RV+LV

26; 28; 30; 32; 35; 40 J

AX>B;B>AX

Table 44.

50 Hz Burst parameters

Parameter Selectable values

Resume at BURST Enabled ; Disabled

Chamber Atrium; RV; LV

Amplitude

1; 2; 3; 4 ; 5; 6; 8 V

Table 44. 50 Hz Burst parameters (continued)

Parameter Selectable values

Pulse Width

VOO Backup (for atrial 50 Hz burst)

0.10; 0.20 … 0.50 … 1.50 ms

On; Off

Pacing Rate 60; 70 … 120 bpm

V. Amplitude

V. Pulse Width

Applies to all ventricular chambers paced.

If V. Pacing

c,d

0.50; 0.75 … 5.00; 5.50; 6.00; 8.00 V

0.10; 0.20 … 1.50 ms

is set to RV, RV→LV, or LV→RV, then backup pacing is delivered to the RV chamber. If V. Pacing is

set to LV, then backup pacing is delivered to the LV chamber.

The default value for this parameter is set according to the permanently programmed settings for bradycardia pacing.

Crosstalk may occur when atrial pacing amplitude is > 6.0 V.

Table 45. Fixed Burst parameters

Parameter Selectable values

Resume at BURST Enabled ; Disabled

Chamber

Atrium; RV; RV+LV; LV

Interval 100; 110 … 600 ms

Amplitude

Pulse Width

VVI Backup (for atrial Fixed Burst)

1; 2; 3; 4 ; 5; 6; 8 V

0.10; 0.20 … 0.50 … 1.50 ms

On; Off

Pacing Rate 60; 70 … 120 bpm

V. Amplitude

V. Pulse Width

If the chamber selected is RV+LV, the delay is set to 2.5 ms with LV pace delivered first.

Applies to all ventricular chambers paced.

If V. Pacing is set to RV, RV→LV, or LV→RV, then backup pacing is delivered to the RV chamber. If V. Pacing is

d,e

0.50; 0.75 … 5.00; 5.50; 6.00; 8.00 V

0.10; 0.20 … 1.50 ms

set to LV, then backup pacing is delivered to the LV chamber.

The default value for this parameter is set according to the permanently programmed settings for bradycardia pacing.

Crosstalk may occur when atrial pacing amplitude is > 6.0 V.

Table 46.

PES parameters

Parameter Selectable values

Resume at DELIVER Enabled ; Disabled

Chamber

Atrium; RV; RV+LV; LV

#S1 1; 2 … 8 … 15

S1S1 100; 110 … 600 … 2000 ms

S1S2 On; Off; 100; 110 … 400 … 600 ms

S2S3 On; Off ; 100; 110 … 600 ms

Table 46. PES parameters (continued)

Parameter Selectable values

S3S4 On; Off ; 100; 110 … 600 ms

Amplitude

Pulse Width

VVI Backup (for atrial PES)

1; 2; 3; 4 ; 5; 6; 8 V

0.10; 0.20 … 0.50 … 1.50 ms

On; Off

Pacing Rate 60; 70 … 120 bpm

V. Amplitude

V. Pulse Width

If the chamber selected is RV+LV, the delay is set to 2.5 ms with LV pace delivered first.

Default value when parameter is programmed to On is 400 ms.

Applies to all ventricular chambers paced.

If V. Pacing

e,f

0.50; 0.75 … 5.00; 5.50; 6.00; 8.00 V

0.10; 0.20 … 1.50 ms

is set to RV, RV→LV, or LV→RV, then backup pacing is delivered to the RV chamber. If V. Pacing is

set to LV, then backup pacing is delivered to the LV chamber.

The default value for this parameter is set according to the permanently programmed settings for bradycardia pacing.

Crosstalk may occur when atrial pacing amplitude is > 6.0 V.

Table 47. Defibrillation parameters

Parameter Selectable values

Chamber RV

Energy 0.4; 0.6 … 1.8; 2; 3 … 16; 18; 20; 22; 24; 25; 26; 28; 30; 32;

35; 40 J

Pathway

If the Active Can/SVC Coil parameter is set to Can Off, the Active Can electrode is not used as part of the high-

AX>B; B>AX

voltage delivery pathway. If the Active Can/SVC Coil parameter is set to SVC Off, the SVC Coil electrode is not used as part of the high-voltage delivery pathway.

Table 48. Cardioversion parameters

Parameter Selectable values

Chamber Atrium; RV

Energy 0.4; 0.6 … 1.8; 2; 3 … 16; 18; 20; 22; 24; 25; 26; 28; 30;

32; 35; 40 J

Pathway

AX>B; B>AX

Minimum R-R (atrial CV only) 400; 410 … 500 … 600 ms

Table 49. Shared ATP parameters

Parameter Selectable values

Minimum Interval (atrial ATP) 100; 110; 120; 130 … 400 ms

Minimum Interval (ventricular ATP) 150; 160 … 200 … 400 ms

Amplitude

Pulse Width

VVI Backup (for atrial ATP studies)

1; 2 … 6 ; 8 V

0.10; 0.20 … 1.50 ms

On; Off

Pacing Rate 60; 70 … 120 bpm

V. Amplitude

V. Pulse Width

Ramp, Burst, Ramp+ and Burst+.

Applies to all ventricular chambers paced.

If V. Pacing is set to RV, RV→LV, or LV→RV, then backup pacing is delivered to the RV chamber. If V. Pacing is

d,e

0.50; 0.75 … 5.00; 5.50; 6.00; 8.00 V

0.10; 0.20 … 1.50 ms

set to LV, then backup pacing is delivered to the LV chamber.

The default value for this parameter is set according to the permanently programmed settings for bradycardia pacing.

Crosstalk may occur when atrial pacing amplitude is > 6.0 V.

Table 50. Ramp parameters

Parameter Selectable values

Chamber

Atrium; RV; RV+LV; LV

Ventricular Ramp study parameters

#Pulses 1; 2 … 6 … 15

%RR Interval 50; 53; 56; 59; 63; 66 … 84; 88; 91; 94; 97 %

Dec/Pulse 0; 10 ; 20; 30; 40 ms

Atrial Ramp study parameters

#Pulses 1; 2 … 6 … 15; 20; 30 … 100

%AA Interval 28; 31; 34; 38; 41 … 59; 63; 66 … 84; 88; 91; 94; 97 %

Dec/Pulse 0; 10 ; 20; 30; 40 ms

If the chamber selected is RV+LV, the delay is set to 2.5 ms with LV pace delivered first.

Table 51.

Burst parameters

Parameter Selectable values

Chamber

RV ; RV+LV; LV

#Pulses 1; 2 … 8 … 15

%RR Interval 50; 53; 56; 59; 63; 66 … 84; 88 ; 91; 94; 97%

If the chamber selected is RV+LV, the delay is set to 2.5 ms with LV pace delivered first.

Table 52. Ramp+ parameters

Parameter Selectable values

Chamber

RV ; RV+LV; LV

#Pulses 1; 2; 3 … 15

R-S1(%RR) 50; 53; 56; 59; 63; 66 … 75 … 84; 88; 91; 94; 97%

S1S2(%RR) 50; 53; 56; 59; 63; 66; 69 … 84; 88; 91; 94; 97%

S2SN(%RR) 50; 53; 56; 59; 63; 66 … 84; 88; 91; 94; 97%

If the chamber selected is RV+LV, the delay is set to 2.5 ms with LV pace delivered first.

Table 53. Burst+ parameters

Parameter Selectable values

Chamber Atrium

#S1 Pulses 1; 2 … 6 … 15; 20; 30 … 100

%AA Interval 28; 31; 34; 38; 41 … 59; 63; 66 … 84; 88; 91 ; 94; 97%

S1S2 Off; 28; 31; 34; 38; 41 … 59; 63; 66 … 84 ; 88; 91; 94;

97%

S2S3 Dec Off; 0; 10; 20 … 80 ms

This value is non-programmable.

Medtronic, Inc.

*M975708A001*

710 Medtronic Parkway Minneapolis, MN 55432 USA www.medtronic.com +1 763 514 4000

Medtronic USA, Inc.

Toll-free in the USA (24-hour technical consultation for physicians and medical professionals) Bradycardia: +1 800 505 4636 Tachycardia: +1 800 723 4636

Technical manuals

www.medtronic.com/manuals

Medtronic DTPA2Q1 Implant Manual

Specifications and Main Features

Frequently Asked Questions

User Manual

Contents

1 System overview

1.1 Introduction

1.2 System description

1.2.1 Usage environments

1.2.2 System components and accessories

1.3 Indications and usage

1.4 Contraindications

1.5 MRI conditions for use

1.6 Pre-implant consideration

1.7 Feature summary

1.7.1 Tachyarrhythmia detection features

1.7.2 Tachyarrhythmia therapy features

1.7.3 Diagnostic data features

1.7.4 Pacing features

1.7.5 Testing features

1.7.6 Additional operations

1.8 Data security

2 Warnings, precautions, and potential adverse events

2.1 General warnings and precautions

2.2 Explant and disposal

2.3 Handling and storage instructions

2.3.1 Device handling

2.3.2 Device storage

2.4 Lead evaluation and lead connection

2.5 Device operation

2.5.1 Pacemaker-dependent patients

2.6 Potential adverse events

3 Clinical data

3.1 Adverse events and clinical trial data

4 Implant procedure

4.1 Preparing for an implant

4.1.1 Instruments, components, and accessories required for an implant

4.1.2 Setting up and starting the device manager

4.1.3 Considerations for preparing for an implant

4.1.4 How to prepare the device for implant

4.2 Selecting and implanting the leads

4.2.1 Selecting the leads

4.2.2 How to verify lead and connector compatibility

Table 1. Lead and connector compatibility

4.2.3 Implanting the leads

4.3 Testing the lead system

4.3.1 How to verify and save the sensing and pacing values

Table 2. Acceptable sensing and pacing values

4.4 Connecting the leads to the device

Figure 1. Lead connector ports

4.4.1 How to connect a lead to the device

Figure 2. Inserting the torque wrench into the setscrew

Figure 3. Confirming the lead connection (DF-1 and IS4-LLLL connectors)

Figure 4. Confirming the lead connection (IS-1 connectors)

4.5 Performing ventricular defibrillation threshold tests

4.5.1 High-voltage implant values

Table 3. High-voltage (HV) therapy values recommended at implant

4.5.2 How to prepare for defibrillation threshold testing

4.6 Positioning and securing the device

4.6.1 How to position and secure the device

Figure 5. Rotating the device to wrap the leads

Figure 6. Locating the suture holes

4.7 Completing the implant procedure

4.7.1 How to complete programming the device

4.7.2 How to assess the performance of the device and the leads

4.8 Replacing a device

4.8.1 How to explant and replace a device

5 Product specifications

5.1 Physical characteristics

Table 4. Physical characteristics

Figure 7. Connector ports and suture holes

Figure 8. Shield graphics: Model DTPA2Q1

5.2 Replacement indicators

Table 5. Replacement indicators

5.3 Projected service life

Table 6. Projected service life

5.3.1 Projected service life considerations

5.4 Energy levels and typical charge times

Table 7. Maximum energy levels and typical full energy charge times

5.5 Magnet application